Drugs interactions for Synjardy®
- 4 Major drug interactions (including ingredients like Abemaciclib, Iomeprol, Procainamide)
- 505 Moderate drug interactions (including ingredients like Acarbose, Acebutolol, Acebutolol)
- 636 Minor drug interactions (including ingredients like Abacavir, Abaloparatide, Acarbose)
1145 interactions for Synjardy®The excretion of Abemaciclib can be decreased when combined with Metformin.The risk or severity of lactic acidosis can be increased when Iomeprol is combined with Metformin.The excretion of Procainamide can be decreased when combined with Metformin.The excretion of Topotecan can be decreased when combined with Metformin.Empagliflozin may increase the hypoglycemic activities of Acarbose.The therapeutic efficacy of Metformin can be increased when used in combination with Acebutolol.The therapeutic efficacy of Empagliflozin can be increased when used in combination with Acebutolol.The risk or severity of lactic acidosis can be increased when Acetazolamide is combined with Metformin.The risk or severity of hypoglycemia can be increased when Acetylsalicylic acid is combined with Metformin.The risk or severity of hypoglycemia can be increased when Acetylsalicylic acid is combined with Empagliflozin.The excretion of Acyclovir can be decreased when combined with Metformin.The risk or severity of hyperglycemia can be increased when Alclometasone is combined with Metformin.The risk or severity of hyperglycemia can be increased when Alclometasone is combined with Empagliflozin.Empagliflozin may increase the hypoglycemic activities of Alogliptin.The serum concentration of Amantadine can be increased when it is combined with Metformin.The risk or severity of hyperglycemia can be increased when Amcinonide is combined with Metformin.The risk or severity of hyperglycemia can be increased when Amcinonide is combined with Empagliflozin.Metformin may decrease the excretion rate of Amikacin which could result in a higher serum level.The serum concentration of Metformin can be increased when it is combined with Amiloride.Aminosalicylic acid may increase the hypoglycemic activities of Metformin.Aminosalicylic acid may increase the hypoglycemic activities of Empagliflozin.The serum concentration of Metformin can be increased when it is combined with Amiodarone.The risk or severity of hypoglycemia can be increased when Amiodarone is combined with Empagliflozin.Amitriptyline may decrease the hypoglycemic activities of Metformin.Amitriptyline may decrease the hypoglycemic activities of Empagliflozin.The risk or severity of hypoglycemia can be increased when Amlodipine is combined with Metformin.The risk or severity of hypoglycemia can be increased when Amlodipine is combined with Empagliflozin.Amobarbital may increase the hypotensive activities of Empagliflozin.Amoxapine may decrease the hypoglycemic activities of Metformin.Amoxapine may decrease the hypoglycemic activities of Empagliflozin.The serum concentration of Metformin can be increased when it is combined with Apalutamide.The therapeutic efficacy of Empagliflozin can be decreased when used in combination with Aripiprazole.The therapeutic efficacy of Empagliflozin can be decreased when used in combination with Arsenic trioxide.The therapeutic efficacy of Empagliflozin can be decreased when used in combination with Articaine.The therapeutic efficacy of Empagliflozin can be decreased when used in combination with Asenapine.The therapeutic efficacy of Empagliflozin can be decreased when used in combination with Atazanavir.The serum concentration of Metformin can be increased when it is combined with Atenolol.The therapeutic efficacy of Empagliflozin can be increased when used in combination with Atenolol.The therapeutic efficacy of Metformin can be decreased when used in combination with Baclofen.The therapeutic efficacy of Empagliflozin can be decreased when used in combination with Baclofen.Balsalazide may increase the hypoglycemic activities of Metformin.Balsalazide may increase the hypoglycemic activities of Empagliflozin.The excretion of Baricitinib can be decreased when combined with Metformin.The risk or severity of hyperglycemia can be increased when Beclomethasone dipropionate is combined with Empagliflozin.The risk or severity of hypoglycemia can be increased when Benazepril is combined with Metformin.The risk or severity of hypoglycemia can be increased when Benazepril is combined with Empagliflozin.The risk or severity of hyperglycemia can be increased when Betamethasone is combined with Empagliflozin.The therapeutic efficacy of Metformin can be increased when used in combination with Betaxolol.The therapeutic efficacy of Empagliflozin can be increased when used in combination with Betaxolol.Bexagliflozin may increase the hypoglycemic activities of Metformin.Empagliflozin may increase the hypoglycemic activities of Bexagliflozin.Bismuth subsalicylate may increase the hypoglycemic activities of Metformin.Bismuth subsalicylate may increase the hypoglycemic activities of Empagliflozin.The therapeutic efficacy of Metformin can be increased when used in combination with Bisoprolol.The therapeutic efficacy of Empagliflozin can be increased when used in combination with Bisoprolol.The therapeutic efficacy of Empagliflozin can be decreased when used in combination with Brexpiprazole.The excretion of Metformin can be decreased when combined with Brigatinib.The risk or severity of hypoglycemia can be increased when Metformin is combined with Bromocriptine.Empagliflozin may increase the hypoglycemic activities of Bromocriptine.The risk or severity of hyperglycemia can be increased when Budesonide is combined with Metformin.The risk or severity of hyperglycemia can be increased when Budesonide is combined with Empagliflozin.The excretion of Metformin can be decreased when combined with Bupropion.Butalbital may increase the hypotensive activities of Empagliflozin.Canagliflozin may increase the hypoglycemic activities of Empagliflozin.The serum concentration of Metformin can be increased when it is combined with Capivasertib.The excretion of Metformin can be decreased when combined with Capmatinib.Metformin may decrease the excretion rate of Capreomycin which could result in a higher serum level.The risk or severity of renal failure, hypotension, and hyperkalemia can be increased when Empagliflozin is combined with Captopril.Metformin may decrease the excretion rate of Carbamazepine which could result in a higher serum level.The therapeutic efficacy of Metformin can be increased when used in combination with Carvedilol.The therapeutic efficacy of Empagliflozin can be increased when used in combination with Carvedilol.Cephalexin may decrease the excretion rate of Metformin which could result in a higher serum level.The therapeutic efficacy of Empagliflozin can be decreased when used in combination with Ceritinib.The serum concentration of Metformin can be increased when it is combined with Chlorpheniramine.The therapeutic efficacy of Empagliflozin can be decreased when used in combination with Chlorpromazine.The serum concentration of Metformin can be increased when it is combined with Choline.Choline salicylate may increase the hypoglycemic activities of Metformin.Choline salicylate may increase the hypoglycemic activities of Empagliflozin.The risk or severity of hyperglycemia can be increased when Ciclesonide is combined with Empagliflozin.The therapeutic efficacy of Metformin can be increased when used in combination with Ciprofloxacin.The therapeutic efficacy of Empagliflozin can be increased when used in combination with Ciprofloxacin.The risk or severity of hypoglycemia can be increased when Citalopram is combined with Metformin.The risk or severity of hypoglycemia can be increased when Citalopram is combined with Empagliflozin.The risk or severity of hypoglycemia can be increased when Clevidipine is combined with Metformin.The risk or severity of hypoglycemia can be increased when Clevidipine is combined with Empagliflozin.The risk or severity of hyperglycemia can be increased when Clobetasol propionate is combined with Empagliflozin.The risk or severity of hyperglycemia can be increased when Clocortolone is combined with Metformin.The risk or severity of hyperglycemia can be increased when Clocortolone is combined with Empagliflozin.Clomipramine may decrease the hypoglycemic activities of Metformin.Clomipramine may decrease the hypoglycemic activities of Empagliflozin.The serum concentration of Metformin can be increased when it is combined with Clopidogrel.The therapeutic efficacy of Empagliflozin can be decreased when used in combination with Clozapine.Metformin may decrease the excretion rate of Colistin which could result in a higher serum level.The therapeutic efficacy of Metformin can be decreased when used in combination with Conjugated estrogens.The therapeutic efficacy of Empagliflozin can be decreased when used in combination with Conjugated estrogens.The risk or severity of hyperglycemia can be increased when Corticotropin is combined with Empagliflozin.The risk or severity of hyperglycemia can be increased when Cortisone acetate is combined with Empagliflozin.The serum concentration of Metformin can be increased when it is combined with Crizotinib.The therapeutic efficacy of Empagliflozin can be decreased when used in combination with Dabrafenib.The therapeutic efficacy of Empagliflozin can be decreased when used in combination with Danazol.Dapagliflozin may increase the hypoglycemic activities of Empagliflozin.The therapeutic efficacy of Empagliflozin can be decreased when used in combination with Darunavir.The risk or severity of hyperglycemia can be increased when Deflazacort is combined with Empagliflozin.The therapeutic efficacy of Metformin can be increased when used in combination with Delafloxacin.The therapeutic efficacy of Empagliflozin can be increased when used in combination with Delafloxacin.Desipramine may decrease the hypoglycemic activities of Metformin.Desipramine may decrease the hypoglycemic activities of Empagliflozin.The therapeutic efficacy of Empagliflozin can be decreased when used in combination with Desogestrel.The risk or severity of hyperglycemia can be increased when Desonide is combined with Metformin.The risk or severity of hyperglycemia can be increased when Desonide is combined with Empagliflozin.The risk or severity of hyperglycemia can be increased when Desoximetasone is combined with Metformin.The risk or severity of hyperglycemia can be increased when Desoximetasone is combined with Empagliflozin.The risk or severity of hypoglycemia can be increased when Desvenlafaxine is combined with Metformin.The risk or severity of hypoglycemia can be increased when Desvenlafaxine is combined with Empagliflozin.The risk or severity of hyperglycemia can be increased when Dexamethasone is combined with Empagliflozin.The risk or severity of hyperglycemia can be increased when Dexamethasone acetate is combined with Metformin.The risk or severity of hyperglycemia can be increased when Dexamethasone acetate is combined with Empagliflozin.The serum concentration of Metformin can be increased when it is combined with Dexchlorpheniramine maleate.The therapeutic efficacy of Empagliflozin can be decreased when used in combination with Diazoxide.The risk or severity of lactic acidosis can be increased when Diclofenamide is combined with Metformin.The therapeutic efficacy of Empagliflozin can be decreased when used in combination with Dienogest.The risk or severity of hyperglycemia can be increased when Diflorasone is combined with Metformin.The risk or severity of hyperglycemia can be increased when Diflorasone is combined with Empagliflozin.Diflunisal may increase the hypoglycemic activities of Metformin.Diflunisal may increase the hypoglycemic activities of Empagliflozin.The risk or severity of hyperglycemia can be increased when Difluprednate is combined with Metformin.The risk or severity of hyperglycemia can be increased when Difluprednate is combined with Empagliflozin.The serum concentration of Digoxin can be increased when it is combined with Metformin.The risk or severity of hypoglycemia can be increased when Diltiazem is combined with Metformin.The risk or severity of hypoglycemia can be increased when Diltiazem is combined with Empagliflozin.The serum concentration of Metformin can be increased when it is combined with Dinoprostone.The serum concentration of Metformin can be increased when it is combined with Diphenhydramine.The risk or severity of hypoglycemia can be increased when Disopyramide is combined with Metformin.Empagliflozin may increase the hypoglycemic activities of Disopyramide.The serum concentration of Dofetilide can be increased when it is combined with Metformin.The serum concentration of Metformin can be increased when it is combined with Dolutegravir.The serum concentration of Dopamine can be increased when it is combined with Metformin.Doxepin may decrease the hypoglycemic activities of Metformin.Doxepin may decrease the hypoglycemic activities of Empagliflozin.The serum concentration of Metformin can be increased when it is combined with Dronedarone.The risk or severity of hypoglycemia can be increased when Metformin is combined with Dulaglutide.Empagliflozin may increase the hypoglycemic activities of Dulaglutide.The risk or severity of hypoglycemia can be increased when Duloxetine is combined with Metformin.The risk or severity of renal failure, hypotension, and hyperkalemia can be increased when Empagliflozin is combined with Enalapril.The risk or severity of renal failure, hypotension, and hyperkalemia can be increased when Empagliflozin is combined with Enalaprilat.The serum concentration of Metformin can be increased when it is combined with Enasidenib.The serum concentration of Metformin can be increased when it is combined with Encorafenib.The therapeutic efficacy of Empagliflozin can be decreased when used in combination with Epinephrine.The serum concentration of Metformin can be increased when it is combined with Erdafitinib.Empagliflozin may increase the hypoglycemic activities of Ertugliflozin.The risk or severity of hypoglycemia can be increased when Escitalopram is combined with Metformin.The risk or severity of hypoglycemia can be increased when Escitalopram is combined with Empagliflozin.The therapeutic efficacy of Metformin can be decreased when used in combination with Estetrol.The therapeutic efficacy of Empagliflozin can be decreased when used in combination with Estetrol.The therapeutic efficacy of Empagliflozin can be decreased when used in combination with Estradiol.The serum concentration of Metformin can be increased when it is combined with Estradiol acetate.The serum concentration of Metformin can be increased when it is combined with Estradiol cypionate.The serum concentration of Metformin can be increased when it is combined with Estradiol valerate.The therapeutic efficacy of Empagliflozin can be decreased when used in combination with Estrone sulfate.Ethanol may increase the hypotensive activities of Empagliflozin.The therapeutic efficacy of Empagliflozin can be decreased when used in combination with Ethinylestradiol.The risk or severity of hypoglycemia can be increased when Ethosuximide is combined with Metformin.The risk or severity of hypoglycemia can be increased when Ethosuximide is combined with Empagliflozin.The therapeutic efficacy of Empagliflozin can be decreased when used in combination with Ethynodiol diacetate.The therapeutic efficacy of Empagliflozin can be decreased when used in combination with Etonogestrel.The therapeutic efficacy of Empagliflozin can be decreased when used in combination with Everolimus.The risk or severity of hypoglycemia can be increased when Exenatide is combined with Metformin.Empagliflozin may increase the hypoglycemic activities of Exenatide.The serum concentration of Metformin can be increased when it is combined with Famotidine.Fedratinib may decrease the excretion rate of Metformin which could result in a higher serum level.The risk or severity of hypoglycemia can be increased when Felodipine is combined with Metformin.The risk or severity of hypoglycemia can be increased when Felodipine is combined with Empagliflozin.The serum concentration of Metformin can be increased when it is combined with Fexinidazole.The risk or severity of hypoglycemia can be increased when Metformin is combined with Fluconazole.The risk or severity of hypoglycemia can be increased when Empagliflozin is combined with Fluconazole.The risk or severity of hyperglycemia can be increased when Fludrocortisone is combined with Empagliflozin.The risk or severity of hyperglycemia can be increased when Flunisolide is combined with Metformin.The risk or severity of hyperglycemia can be increased when Flunisolide is combined with Empagliflozin.The risk or severity of hyperglycemia can be increased when Fluocinolone acetonide is combined with Metformin.The risk or severity of hyperglycemia can be increased when Fluocinolone acetonide is combined with Empagliflozin.The risk or severity of hyperglycemia can be increased when Fluocinonide is combined with Metformin.The risk or severity of hyperglycemia can be increased when Fluocinonide is combined with Empagliflozin.The risk or severity of hyperglycemia can be increased when Fluorometholone is combined with Empagliflozin.The risk or severity of hypoglycemia can be increased when Fluoxetine is combined with Metformin.The risk or severity of hypoglycemia can be increased when Fluoxetine is combined with Empagliflozin.The risk or severity of hyperglycemia can be increased when Flurandrenolide is combined with Metformin.The risk or severity of hyperglycemia can be increased when Flurandrenolide is combined with Empagliflozin.The serum concentration of Metformin can be increased when it is combined with Flurazepam.The risk or severity of hyperglycemia can be increased when Fluticasone furoate is combined with Empagliflozin.The risk or severity of hyperglycemia can be increased when Fluticasone propionate is combined with Metformin.The risk or severity of hyperglycemia can be increased when Fluticasone propionate is combined with Empagliflozin.The risk or severity of hypoglycemia can be increased when Fluvoxamine is combined with Metformin.The risk or severity of hypoglycemia can be increased when Fluvoxamine is combined with Empagliflozin.The therapeutic efficacy of Empagliflozin can be decreased when used in combination with Fosamprenavir.The risk or severity of renal failure, hypotension, and hyperkalemia can be increased when Empagliflozin is combined with Fosinopril.The excretion of Ganciclovir can be decreased when combined with Metformin.The therapeutic efficacy of Metformin can be increased when used in combination with Gatifloxacin.The therapeutic efficacy of Empagliflozin can be increased when used in combination with Gatifloxacin.The therapeutic efficacy of Metformin can be increased when used in combination with Gemifloxacin.The therapeutic efficacy of Empagliflozin can be increased when used in combination with Gemifloxacin.Metformin may decrease the excretion rate of Gentamicin which could result in a higher serum level.The excretion of Metformin can be decreased when combined with Glasdegib.Empagliflozin may increase the hypoglycemic activities of Glimepiride.Empagliflozin may increase the hypoglycemic activities of Glipizide.Empagliflozin may increase the hypoglycemic activities of Glyburide.The therapeutic efficacy of Empagliflozin can be decreased when used in combination with Goserelin.The serum concentration of Metformin can be increased when it is combined with Guanidine.The risk or severity of hyperglycemia can be increased when Halcinonide is combined with Metformin.The risk or severity of hyperglycemia can be increased when Halcinonide is combined with Empagliflozin.The therapeutic efficacy of Empagliflozin can be decreased when used in combination with Haloperidol.The serum concentration of Histamine can be increased when it is combined with Metformin.The therapeutic efficacy of Empagliflozin can be decreased when used in combination with Histrelin.The risk or severity of hyperglycemia can be increased when Hydrocortisone is combined with Empagliflozin.The risk or severity of hyperglycemia can be increased when Hydrocortisone acetate is combined with Metformin.The risk or severity of hyperglycemia can be increased when Hydrocortisone acetate is combined with Empagliflozin.The risk or severity of hyperglycemia can be increased when Hydrocortisone butyrate is combined with Metformin.The risk or severity of hyperglycemia can be increased when Hydrocortisone butyrate is combined with Empagliflozin.The risk or severity of hyperglycemia can be increased when Hydrocortisone probutate is combined with Metformin.The risk or severity of hyperglycemia can be increased when Hydrocortisone probutate is combined with Empagliflozin.The risk or severity of hyperglycemia can be increased when Hydrocortisone succinate is combined with Metformin.The risk or severity of hyperglycemia can be increased when Hydrocortisone succinate is combined with Empagliflozin.The risk or severity of hyperglycemia can be increased when Hydrocortisone valerate is combined with Metformin.The risk or severity of hyperglycemia can be increased when Hydrocortisone valerate is combined with Empagliflozin.The therapeutic efficacy of Metformin can be decreased when used in combination with Hydroflumethiazide.The therapeutic efficacy of Metformin can be increased when used in combination with Hydroxychloroquine.The therapeutic efficacy of Empagliflozin can be increased when used in combination with Hydroxychloroquine.The therapeutic efficacy of Empagliflozin can be decreased when used in combination with Hydroxyprogesterone caproate.The therapeutic efficacy of Empagliflozin can be decreased when used in combination with Iloperidone.The serum concentration of Metformin can be increased when it is combined with Imatinib.Imipramine may decrease the hypoglycemic activities of Metformin.Imipramine may decrease the hypoglycemic activities of Empagliflozin.The therapeutic efficacy of Empagliflozin can be decreased when used in combination with Indinavir.The risk or severity of hypoglycemia can be increased when Indomethacin is combined with Metformin.The risk or severity of hypoglycemia can be increased when Indomethacin is combined with Empagliflozin.The risk or severity of adverse effects can be increased when Insulin aspart is combined with Metformin.The risk or severity of hypoglycemia can be increased when Empagliflozin is combined with Insulin aspart.The risk or severity of adverse effects can be increased when Insulin degludec is combined with Metformin.The risk or severity of hypoglycemia can be increased when Empagliflozin is combined with Insulin degludec.The risk or severity of adverse effects can be increased when Insulin detemir is combined with Metformin.The risk or severity of hypoglycemia can be increased when Empagliflozin is combined with Insulin detemir.The risk or severity of adverse effects can be increased when Insulin glargine is combined with Metformin.The risk or severity of hypoglycemia can be increased when Empagliflozin is combined with Insulin glargine.The risk or severity of adverse effects can be increased when Insulin glulisine is combined with Metformin.The risk or severity of hypoglycemia can be increased when Empagliflozin is combined with Insulin glulisine.The risk or severity of adverse effects can be increased when Insulin human is combined with Metformin.The risk or severity of hypoglycemia can be increased when Empagliflozin is combined with Insulin human.The risk or severity of adverse effects can be increased when Insulin lispro is combined with Metformin.The risk or severity of hypoglycemia can be increased when Empagliflozin is combined with Insulin lispro.The risk or severity of adverse effects can be increased when Iodixanol is combined with Metformin.The risk or severity of adverse effects can be increased when Iohexol is combined with Metformin.The risk or severity of adverse effects can be increased when Iopamidol is combined with Metformin.The risk or severity of lactic acidosis can be increased when Iopromide is combined with Metformin.The risk or severity of adverse effects can be increased when Ioversol is combined with Metformin.The serum concentration of Metformin can be increased when it is combined with Isavuconazonium.Isocarboxazid may increase the orthostatic hypotensive activities of Empagliflozin.The therapeutic efficacy of Empagliflozin can be decreased when used in combination with Isoniazid.The risk or severity of hypoglycemia can be increased when Isradipine is combined with Metformin.The risk or severity of hypoglycemia can be increased when Isradipine is combined with Empagliflozin.The excretion of Metformin can be decreased when combined with Istradefylline.The therapeutic efficacy of Metformin can be increased when used in combination with Labetalol.The therapeutic efficacy of Empagliflozin can be increased when used in combination with Labetalol.The therapeutic efficacy of Empagliflozin can be decreased when used in combination with Lanreotide.The serum concentration of Metformin can be increased when it is combined with Lenvatinib.The therapeutic efficacy of Empagliflozin can be decreased when used in combination with Leuprolide.The risk or severity of hypoglycemia can be increased when Levamlodipine is combined with Metformin.The risk or severity of hypoglycemia can be increased when Levamlodipine is combined with Empagliflozin.The therapeutic efficacy of Metformin can be increased when used in combination with Levofloxacin.The therapeutic efficacy of Empagliflozin can be increased when used in combination with Levofloxacin.The serum concentration of Metformin can be increased when it is combined with Levoketoconazole.The risk or severity of hypoglycemia can be increased when Levomilnacipran is combined with Metformin.The risk or severity of hypoglycemia can be increased when Levomilnacipran is combined with Empagliflozin.The therapeutic efficacy of Empagliflozin can be decreased when used in combination with Levonorgestrel.The therapeutic efficacy of Metformin can be decreased when used in combination with Levothyroxine.Linezolid may increase the orthostatic hypotensive activities of Empagliflozin.The therapeutic efficacy of Metformin can be decreased when used in combination with Liothyronine.The therapeutic efficacy of Empagliflozin can be decreased when used in combination with Liothyronine.The risk or severity of hypoglycemia can be increased when Lipoic acid is combined with Empagliflozin.The risk or severity of hypoglycemia can be increased when Liraglutide is combined with Metformin.Empagliflozin may increase the hypoglycemic activities of Liraglutide.The risk or severity of renal failure, hypotension, and hyperkalemia can be increased when Empagliflozin is combined with Lisinopril.The risk or severity of hypoglycemia can be increased when Metformin is combined with Lixisenatide.Empagliflozin may increase the hypoglycemic activities of Lixisenatide.The therapeutic efficacy of Metformin can be increased when used in combination with Lomefloxacin.The therapeutic efficacy of Empagliflozin can be increased when used in combination with Lomefloxacin.The therapeutic efficacy of Metformin can be decreased when used in combination with Lonapegsomatropin.The therapeutic efficacy of Empagliflozin can be decreased when used in combination with Lonapegsomatropin.The therapeutic efficacy of Empagliflozin can be decreased when used in combination with Lopinavir.The therapeutic efficacy of Empagliflozin can be decreased when used in combination with Lurasidone.The risk or severity of hypoglycemia can be increased when Magnesium sulfate is combined with Metformin.The risk or severity of hypoglycemia can be increased when Magnesium sulfate is combined with Empagliflozin.The risk or severity of hypoglycemia can be increased when Mecasermin is combined with Metformin.Empagliflozin may increase the hypoglycemic activities of Mecasermin.The therapeutic efficacy of Empagliflozin can be decreased when used in combination with Medroxyprogesterone acetate.The risk or severity of hyperglycemia can be increased when Medrysone is combined with Metformin.The risk or severity of hyperglycemia can be increased when Medrysone is combined with Empagliflozin.The therapeutic efficacy of Empagliflozin can be decreased when used in combination with Megestrol acetate.Mesalazine may increase the hypoglycemic activities of Metformin.Mesalazine may increase the hypoglycemic activities of Empagliflozin.The risk or severity of lactic acidosis can be increased when Methazolamide is combined with Metformin.Methohexital may increase the hypotensive activities of Empagliflozin.The risk or severity of hypoglycemia can be increased when Methsuximide is combined with Metformin.The risk or severity of hypoglycemia can be increased when Methsuximide is combined with Empagliflozin.Methyl salicylate may increase the hypoglycemic activities of Metformin.Methyl salicylate may increase the hypoglycemic activities of Empagliflozin.The serum concentration of Metformin can be increased when it is combined with Methylene blue.Methylene blue may increase the orthostatic hypotensive activities of Empagliflozin.The risk or severity of hyperglycemia can be increased when Methylprednisolone is combined with Empagliflozin.The risk or severity of hyperglycemia can be increased when Methylprednisolone hemisuccinate is combined with Metformin.The risk or severity of hyperglycemia can be increased when Methylprednisolone hemisuccinate is combined with Empagliflozin.The therapeutic efficacy of Metformin can be increased when used in combination with Metoprolol.The therapeutic efficacy of Empagliflozin can be increased when used in combination with Metoprolol.The risk or severity of hypoglycemia can be increased when Mifepristone is combined with Metformin.Empagliflozin may increase the hypoglycemic activities of Mifepristone.Empagliflozin may increase the hypoglycemic activities of Miglitol.The risk or severity of hypoglycemia can be increased when Milnacipran is combined with Metformin.The risk or severity of hypoglycemia can be increased when Milnacipran is combined with Empagliflozin.The risk or severity of renal failure, hypotension, and hyperkalemia can be increased when Empagliflozin is combined with Moexipril.The risk or severity of hyperglycemia can be increased when Mometasone furoate is combined with Empagliflozin.The therapeutic efficacy of Metformin can be increased when used in combination with Moxifloxacin.The therapeutic efficacy of Empagliflozin can be increased when used in combination with Moxifloxacin.The therapeutic efficacy of Metformin can be increased when used in combination with Nadolol.The therapeutic efficacy of Empagliflozin can be increased when used in combination with Nadolol.Empagliflozin may increase the hypoglycemic activities of Nateglinide.The therapeutic efficacy of Metformin can be increased when used in combination with Nebivolol.The therapeutic efficacy of Empagliflozin can be increased when used in combination with Nebivolol.The risk or severity of hypoglycemia can be increased when Nefazodone is combined with Metformin.The risk or severity of hypoglycemia can be increased when Nefazodone is combined with Empagliflozin.The therapeutic efficacy of Empagliflozin can be decreased when used in combination with Nelfinavir.Metformin may decrease the excretion rate of Neomycin which could result in a higher serum level.The therapeutic efficacy of Empagliflozin can be decreased when used in combination with Niacin.The risk or severity of hypoglycemia can be increased when Nicardipine is combined with Metformin.The risk or severity of hypoglycemia can be increased when Nicardipine is combined with Empagliflozin.The serum concentration of Metformin can be increased when it is combined with Nicotine.The risk or severity of hypoglycemia can be increased when Nifedipine is combined with Metformin.The risk or severity of hypoglycemia can be increased when Nifedipine is combined with Empagliflozin.The therapeutic efficacy of Empagliflozin can be decreased when used in combination with Nilotinib.The risk or severity of hypoglycemia can be increased when Nimodipine is combined with Metformin.The risk or severity of hypoglycemia can be increased when Nimodipine is combined with Empagliflozin.The risk or severity of hypoglycemia can be increased when Nisoldipine is combined with Metformin.The risk or severity of hypoglycemia can be increased when Nisoldipine is combined with Empagliflozin.The serum concentration of Norepinephrine can be increased when it is combined with Metformin.The therapeutic efficacy of Empagliflozin can be decreased when used in combination with Norethisterone.The therapeutic efficacy of Empagliflozin can be decreased when used in combination with Norgestimate.Nortriptyline may decrease the hypoglycemic activities of Metformin.Nortriptyline may decrease the hypoglycemic activities of Empagliflozin.The therapeutic efficacy of Metformin can be decreased when used in combination with Octreotide.The therapeutic efficacy of Empagliflozin can be decreased when used in combination with Octreotide.The therapeutic efficacy of Metformin can be increased when used in combination with Ofloxacin.The therapeutic efficacy of Empagliflozin can be increased when used in combination with Ofloxacin.The therapeutic efficacy of Empagliflozin can be decreased when used in combination with Olanzapine.Olsalazine may increase the hypoglycemic activities of Metformin.Olsalazine may increase the hypoglycemic activities of Empagliflozin.The therapeutic efficacy of Empagliflozin can be decreased when used in combination with Paliperidone.The risk or severity of hypoglycemia can be increased when Paroxetine is combined with Metformin.The risk or severity of hypoglycemia can be increased when Paroxetine is combined with Empagliflozin.The therapeutic efficacy of Empagliflozin can be decreased when used in combination with Pasireotide.Patiromer can cause a decrease in the absorption of Metformin resulting in a reduced serum concentration and potentially a decrease in efficacy.The risk or severity of hypoglycemia can be increased when Pegvisomant is combined with Metformin.The risk or severity of hypoglycemia can be increased when Pegvisomant is combined with Empagliflozin.Metformin may decrease the excretion rate of Pemetrexed which could result in a higher serum level.Empagliflozin may increase the hypoglycemic activities of Pentamidine.Pentobarbital may increase the hypotensive activities of Empagliflozin.Metformin may decrease the excretion rate of Pentostatin which could result in a higher serum level.The risk or severity of renal failure, hypotension, and hyperkalemia can be increased when Empagliflozin is combined with Perindopril.The excretion of Metformin can be decreased when combined with Pexidartinib.Phenelzine may increase the orthostatic hypotensive activities of Empagliflozin.Phenobarbital may increase the hypotensive activities of Empagliflozin.The serum concentration of Metformin can be increased when it is combined with Phenoxybenzamine.The therapeutic efficacy of Metformin can be increased when used in combination with Phentermine.The therapeutic efficacy of Empagliflozin can be increased when used in combination with Phentermine.The therapeutic efficacy of Empagliflozin can be decreased when used in combination with Phenytoin.The risk or severity of hypoglycemia can be increased when Pinaverium is combined with Metformin.The risk or severity of hypoglycemia can be increased when Pinaverium is combined with Empagliflozin.The therapeutic efficacy of Metformin can be increased when used in combination with Pindolol.The therapeutic efficacy of Empagliflozin can be increased when used in combination with Pindolol.Empagliflozin may increase the hypoglycemic activities of Pioglitazone.Metformin may decrease the excretion rate of Plazomicin which could result in a higher serum level.The excretion of Metformin can be decreased when combined with Pralsetinib.The risk or severity of hypoglycemia can be increased when Pramlintide is combined with Metformin.Empagliflozin may increase the hypoglycemic activities of Pramlintide.The risk or severity of hyperglycemia can be increased when Prednicarbate is combined with Metformin.The risk or severity of hyperglycemia can be increased when Prednicarbate is combined with Empagliflozin.The risk or severity of hyperglycemia can be increased when Prednisolone is combined with Empagliflozin.The risk or severity of hyperglycemia can be increased when Prednisolone acetate is combined with Metformin.The risk or severity of hyperglycemia can be increased when Prednisolone acetate is combined with Empagliflozin.The risk or severity of hyperglycemia can be increased when Prednisolone phosphate is combined with Metformin.The risk or severity of hyperglycemia can be increased when Prednisolone phosphate is combined with Empagliflozin.The risk or severity of hyperglycemia can be increased when Prednisone is combined with Empagliflozin.The risk or severity of hypoglycemia can be increased when Pregabalin is combined with Metformin.The risk or severity of hypoglycemia can be increased when Pregabalin is combined with Empagliflozin.Primidone may increase the hypotensive activities of Empagliflozin.The serum concentration of Metformin can be increased when it is combined with Probenecid.Procaine may increase the orthostatic hypotensive activities of Empagliflozin.Procarbazine may increase the orthostatic hypotensive activities of Empagliflozin.The therapeutic efficacy of Empagliflozin can be decreased when used in combination with Progesterone.The therapeutic efficacy of Metformin can be increased when used in combination with Propafenone.The therapeutic efficacy of Empagliflozin can be increased when used in combination with Propafenone.The therapeutic efficacy of Metformin can be increased when used in combination with Propranolol.The therapeutic efficacy of Empagliflozin can be increased when used in combination with Propranolol.Protriptyline may decrease the hypoglycemic activities of Metformin.Protriptyline may decrease the hypoglycemic activities of Empagliflozin.The therapeutic efficacy of Empagliflozin can be decreased when used in combination with Pseudoephedrine.The excretion of Metformin can be decreased when combined with Pyrimethamine.The therapeutic efficacy of Empagliflozin can be decreased when used in combination with Quetiapine.The risk or severity of renal failure, hypotension, and hyperkalemia can be increased when Empagliflozin is combined with Quinapril.Metformin may decrease the excretion rate of Quinidine which could result in a higher serum level.The risk or severity of hypoglycemia can be increased when Quinine is combined with Metformin.Empagliflozin may increase the hypoglycemic activities of Quinine.The risk or severity of renal failure, hypotension, and hyperkalemia can be increased when Empagliflozin is combined with Ramipril.The serum concentration of Ranitidine can be increased when it is combined with Metformin.The serum concentration of Metformin can be increased when it is combined with Ranolazine.Rasagiline may increase the orthostatic hypotensive activities of Empagliflozin.The excretion of Relebactam can be decreased when combined with Metformin.Empagliflozin may increase the hypoglycemic activities of Repaglinide.The excretion of Metformin can be decreased when combined with Repotrectinib.The serum concentration of Metformin can be increased when it is combined with Risdiplam.The therapeutic efficacy of Empagliflozin can be decreased when used in combination with Ritonavir.Empagliflozin may increase the hypoglycemic activities of Rosiglitazone.Safinamide may increase the orthostatic hypotensive activities of Empagliflozin.Salicylic acid may increase the hypoglycemic activities of Metformin.Salicylic acid may increase the hypoglycemic activities of Empagliflozin.The serum concentration of Metformin can be increased when it is combined with Salmeterol.The therapeutic efficacy of Empagliflozin can be decreased when used in combination with Saquinavir.Empagliflozin may increase the hypoglycemic activities of Saxagliptin.Secobarbital may increase the hypotensive activities of Empagliflozin.Selegiline may increase the orthostatic hypotensive activities of Empagliflozin.The risk or severity of hypoglycemia can be increased when Metformin is combined with Semaglutide.Empagliflozin may increase the hypoglycemic activities of Semaglutide.The risk or severity of hypoglycemia can be increased when Sertraline is combined with Metformin.The risk or severity of hypoglycemia can be increased when Sertraline is combined with Empagliflozin.The therapeutic efficacy of Empagliflozin can be decreased when used in combination with Sirolimus.Empagliflozin may increase the hypoglycemic activities of Sitagliptin.The risk or severity of hypotension can be increased when Sodium ferric gluconate complex is combined with Empagliflozin.The therapeutic efficacy of Metformin can be decreased when used in combination with Somapacitan.The therapeutic efficacy of Empagliflozin can be decreased when used in combination with Somapacitan.Somatotropin may decrease the hypoglycemic activities of Metformin.Somatotropin may decrease the hypoglycemic activities of Empagliflozin.The therapeutic efficacy of Metformin can be decreased when used in combination with Somatrogon.The therapeutic efficacy of Empagliflozin can be decreased when used in combination with Somatrogon.The risk or severity of hypoglycemia can be increased when Metformin is combined with Sotagliflozin.Empagliflozin may increase the hypoglycemic activities of Sotagliflozin.The risk or severity of hypoglycemia can be increased when Sotalol is combined with Metformin.The risk or severity of hypoglycemia can be increased when Sotalol is combined with Empagliflozin.Metformin may decrease the excretion rate of Streptomycin which could result in a higher serum level.The risk or severity of hypoglycemia can be increased when Sulfadiazine is combined with Metformin.Empagliflozin may increase the hypoglycemic activities of Sulfadiazine.The risk or severity of hypoglycemia can be increased when Sulfamethoxazole is combined with Metformin.Empagliflozin may increase the hypoglycemic activities of Sulfamethoxazole.Sulfasalazine may increase the hypoglycemic activities of Metformin.Sulfasalazine may increase the hypoglycemic activities of Empagliflozin.The risk or severity of hypoglycemia can be increased when Sunitinib is combined with Metformin.Empagliflozin may increase the hypoglycemic activities of Sunitinib.The therapeutic efficacy of Empagliflozin can be decreased when used in combination with Tacrolimus.The serum concentration of Metformin can be increased when it is combined with Tafenoquine.The excretion of Metformin can be decreased when combined with Tazemetostat.The therapeutic efficacy of Empagliflozin can be decreased when used in combination with Temsirolimus.The serum concentration of Tenofovir alafenamide can be increased when it is combined with Metformin.The therapeutic efficacy of Empagliflozin can be decreased when used in combination with Teprotumumab.The serum concentration of Metformin can be increased when it is combined with Thiamine.The therapeutic efficacy of Metformin can be decreased when used in combination with Thyroid, porcine.Thyroid, porcine may decrease the hypoglycemic activities of Empagliflozin.The therapeutic efficacy of Metformin can be decreased when used in combination with Thyrotropin alfa.Thyrotropin alfa may decrease the hypoglycemic activities of Empagliflozin.The therapeutic efficacy of Metformin can be increased when used in combination with Timolol.The therapeutic efficacy of Empagliflozin can be increased when used in combination with Timolol.The therapeutic efficacy of Empagliflozin can be decreased when used in combination with Tipranavir.The risk or severity of hypoglycemia can be increased when Metformin is combined with Tirzepatide.Empagliflozin may increase the hypoglycemic activities of Tirzepatide.The risk or severity of hyperglycemia can be increased when Tixocortol is combined with Metformin.The risk or severity of hyperglycemia can be increased when Tixocortol is combined with Empagliflozin.Metformin may decrease the excretion rate of Tobramycin which could result in a higher serum level.The risk or severity of hypoglycemia can be increased when Tolazamide is combined with Metformin.Empagliflozin may increase the hypoglycemic activities of Tolazamide.The risk or severity of lactic acidosis can be increased when Topiramate is combined with Metformin.The risk or severity of renal failure, hypotension, and hyperkalemia can be increased when Empagliflozin is combined with Trandolapril.Tranylcypromine may increase the orthostatic hypotensive activities of Empagliflozin.The risk or severity of hyperglycemia can be increased when Triamcinolone is combined with Empagliflozin.The serum concentration of Metformin can be increased when it is combined with Trilaciclib.The serum concentration of Metformin can be increased when it is combined with Trimethoprim.Trimipramine may decrease the hypoglycemic activities of Metformin.Trimipramine may decrease the hypoglycemic activities of Empagliflozin.The therapeutic efficacy of Empagliflozin can be decreased when used in combination with Triptorelin.Trolamine salicylate may increase the hypoglycemic activities of Metformin.Trolamine salicylate may increase the hypoglycemic activities of Empagliflozin.The therapeutic efficacy of Metformin can be increased when used in combination with Trovafloxacin.The therapeutic efficacy of Empagliflozin can be increased when used in combination with Trovafloxacin.The serum concentration of Metformin can be increased when it is combined with Tucatinib.The risk or severity of hypoglycemia can be increased when Ubidecarenone is combined with Metformin.The risk or severity of hypoglycemia can be increased when Ubidecarenone is combined with Empagliflozin.The risk or severity of hyperglycemia can be increased when Ulobetasol is combined with Metformin.The risk or severity of hyperglycemia can be increased when Ulobetasol is combined with Empagliflozin.The risk or severity of hyperglycemia can be increased when Vamorolone is combined with Metformin.The risk or severity of hyperglycemia can be increased when Vamorolone is combined with Empagliflozin.Metformin may decrease the excretion rate of Vancomycin which could result in a higher serum level.The serum concentration of Metformin can be increased when it is combined with Vandetanib.The serum concentration of Metformin can be increased when it is combined with Varenicline.The risk or severity of hypoglycemia can be increased when Venlafaxine is combined with Metformin.The risk or severity of hypoglycemia can be increased when Venlafaxine is combined with Empagliflozin.The risk or severity of hypoglycemia can be increased when Verapamil is combined with Metformin.The risk or severity of hypoglycemia can be increased when Verapamil is combined with Empagliflozin.The serum concentration of Metformin can be increased when it is combined with Vimseltinib.The therapeutic efficacy of Empagliflozin can be decreased when used in combination with Vorinostat.Metformin may decrease the excretion rate of Warfarin which could result in a higher serum level.The risk or severity of hypoglycemia can be increased when Xylometazoline is combined with Metformin.The risk or severity of hypoglycemia can be increased when Xylometazoline is combined with Empagliflozin.The risk or severity of hypoglycemia can be increased when Ziconotide is combined with Metformin.The risk or severity of hypoglycemia can be increased when Ziconotide is combined with Empagliflozin.The therapeutic efficacy of Empagliflozin can be decreased when used in combination with Ziprasidone.The risk or severity of lactic acidosis can be increased when Zonisamide is combined with Metformin.Metformin may decrease the excretion rate of Abacavir which could result in a higher serum level.The risk or severity of adverse effects can be increased when Abaloparatide is combined with Empagliflozin.The serum concentration of Metformin can be decreased when it is combined with Acarbose.Aceclofenac may decrease the excretion rate of Metformin which could result in a higher serum level.Empagliflozin may increase the diuretic activities of Acetazolamide.The therapeutic efficacy of Metformin can be increased when used in combination with Acetyl sulfisoxazole.The therapeutic efficacy of Empagliflozin can be increased when used in combination with Acetyl sulfisoxazole.Metformin may decrease the excretion rate of Aclidinium which could result in a higher serum level.Metformin may decrease the excretion rate of Acrivastine which could result in a higher serum level.Adefovir dipivoxil may decrease the excretion rate of Metformin which could result in a higher serum level.The therapeutic efficacy of Metformin can be decreased when used in combination with Albuterol.The therapeutic efficacy of Empagliflozin can be decreased when used in combination with Albuterol.Metformin may decrease the excretion rate of Albutrepenonacog alfa which could result in a higher serum level.Aldesleukin may decrease the excretion rate of Metformin which could result in a higher serum level.The risk or severity of adverse effects can be increased when Aldesleukin is combined with Empagliflozin.The risk or severity of adverse effects can be increased when Aliskiren is combined with Empagliflozin.Metformin may decrease the excretion rate of Allopurinol which could result in a higher serum level.Metformin may decrease the excretion rate of Almasilate which could result in a higher serum level.Metformin may decrease the excretion rate of Almotriptan which could result in a higher serum level.Metformin may decrease the excretion rate of Alprazolam which could result in a higher serum level.Empagliflozin may increase the hypotensive activities of Ambrisentan.The risk or severity of adverse effects can be increased when Amifostine is combined with Empagliflozin.Empagliflozin may increase the diuretic activities of Amiloride.Metformin may decrease the excretion rate of Ammonium chloride which could result in a higher serum level.Metformin may decrease the excretion rate of Amoxicillin which could result in a higher serum level.Amphetamine may decrease the excretion rate of Metformin which could result in a higher serum level.Amphotericin B may decrease the excretion rate of Metformin which could result in a higher serum level.The risk or severity of adverse effects can be increased when Amphotericin B is combined with Empagliflozin.Metformin may decrease the excretion rate of Ampicillin which could result in a higher serum level.The risk or severity of adverse effects can be increased when Amyl Nitrite is combined with Empagliflozin.Antipyrine may decrease the excretion rate of Metformin which could result in a higher serum level.Metformin may decrease the excretion rate of Antithrombin III human which could result in a higher serum level.The risk or severity of adverse effects can be increased when Apomorphine is combined with Empagliflozin.Metformin may decrease the excretion rate of Apremilast which could result in a higher serum level.Empagliflozin may increase the hypotensive activities of Aprocitentan.Metformin may decrease the excretion rate of Arformoterol which could result in a higher serum level.The serum concentration of Metformin can be increased when it is combined with Arimoclomol.The therapeutic efficacy of Metformin can be decreased when used in combination with Aripiprazole.Aripiprazole lauroxil may increase the hypotensive activities of Empagliflozin.The therapeutic efficacy of Metformin can be decreased when used in combination with Arsenic trioxide.The therapeutic efficacy of Metformin can be decreased when used in combination with Articaine.The therapeutic efficacy of Metformin can be decreased when used in combination with Asenapine.The therapeutic efficacy of Metformin can be decreased when used in combination with Atazanavir.Atomoxetine may decrease the excretion rate of Metformin which could result in a higher serum level.Metformin may increase the hypolipidaemic activities of Atorvastatin.Metformin may decrease the excretion rate of Auranofin which could result in a higher serum level.The risk or severity of hypotension can be increased when Avanafil is combined with Empagliflozin.Metformin may decrease the excretion rate of Azacitidine which could result in a higher serum level.Metformin may decrease the excretion rate of Azathioprine which could result in a higher serum level.Metformin may decrease the excretion rate of Azelaic acid which could result in a higher serum level.The risk or severity of adverse effects can be increased when Azilsartan medoxomil is combined with Empagliflozin.Metformin may decrease the excretion rate of Aztreonam which could result in a higher serum level.Bacitracin may decrease the excretion rate of Metformin which could result in a higher serum level.The therapeutic efficacy of Metformin can be decreased when used in combination with Beclomethasone dipropionate.The therapeutic efficacy of Metformin can be decreased when used in combination with Bendroflumethiazide.Empagliflozin may increase the diuretic activities of Bendroflumethiazide.Benzatropine may decrease the excretion rate of Metformin which could result in a higher serum level.Metformin may decrease the excretion rate of Benznidazole which could result in a higher serum level.Metformin may decrease the excretion rate of Bepotastine which could result in a higher serum level.The therapeutic efficacy of Metformin can be decreased when used in combination with Betamethasone.Metformin may decrease the excretion rate of Bicisate which could result in a higher serum level.The excretion of Metformin can be decreased when combined with Bictegravir.Metformin may decrease the excretion rate of Bismuth subgallate which could result in a higher serum level.Bleomycin may decrease the excretion rate of Metformin which could result in a higher serum level.The therapeutic efficacy of Metformin can be increased when used in combination with Bosentan.The therapeutic efficacy of Empagliflozin can be increased when used in combination with Bosentan.The risk or severity of adverse effects can be increased when Bretylium is combined with Empagliflozin.The therapeutic efficacy of Metformin can be decreased when used in combination with Brexpiprazole.Empagliflozin may increase the diuretic activities of Brinzolamide.Metformin may decrease the excretion rate of Brivaracetam which could result in a higher serum level.Bromotheophylline may increase the excretion rate of Metformin which could result in a lower serum level and potentially a reduction in efficacy.Empagliflozin may increase the diuretic activities of Bromotheophylline.The therapeutic efficacy of Metformin can be decreased when used in combination with Bumetanide.Empagliflozin may increase the diuretic activities of Bumetanide.The risk or severity of adverse effects can be increased when Bupivacaine is combined with Empagliflozin.Metformin may decrease the excretion rate of Buspirone which could result in a higher serum level.The risk or severity of adverse effects can be increased when Candesartan cilexetil is combined with Empagliflozin.Metformin may decrease the excretion rate of Capecitabine which could result in a higher serum level.The risk or severity of lactic acidosis can be increased when Captopril is combined with Metformin.Carbidopa may decrease the excretion rate of Metformin which could result in a higher serum level.Carboplatin may decrease the excretion rate of Metformin which could result in a higher serum level.Carmustine may decrease the excretion rate of Metformin which could result in a higher serum level.Cefaclor may decrease the excretion rate of Metformin which could result in a higher serum level.Cefadroxil may decrease the excretion rate of Metformin which could result in a higher serum level.Cefazolin may decrease the excretion rate of Metformin which could result in a higher serum level.Metformin may decrease the excretion rate of Cefdinir which could result in a higher serum level.Cefditoren may decrease the excretion rate of Metformin which could result in a higher serum level.Cefepime may decrease the excretion rate of Metformin which could result in a higher serum level.Cefotaxime may decrease the excretion rate of Metformin which could result in a higher serum level.Cefotetan may decrease the excretion rate of Metformin which could result in a higher serum level.Cefoxitin may decrease the excretion rate of Metformin which could result in a higher serum level.Cefpodoxime may decrease the excretion rate of Metformin which could result in a higher serum level.Cefprozil may decrease the excretion rate of Metformin which could result in a higher serum level.Ceftaroline fosamil may decrease the excretion rate of Metformin which could result in a higher serum level.Ceftazidime may decrease the excretion rate of Metformin which could result in a higher serum level.Ceftibuten may decrease the excretion rate of Metformin which could result in a higher serum level.Ceftizoxime may decrease the excretion rate of Metformin which could result in a higher serum level.Metformin may decrease the excretion rate of Ceftolozane which could result in a higher serum level.Ceftriaxone may decrease the excretion rate of Metformin which could result in a higher serum level.Cefuroxime may decrease the excretion rate of Metformin which could result in a higher serum level.The therapeutic efficacy of Metformin can be increased when used in combination with Celecoxib.The therapeutic efficacy of Empagliflozin can be increased when used in combination with Celecoxib.The therapeutic efficacy of Metformin can be decreased when used in combination with Ceritinib.Metformin may decrease the excretion rate of Certolizumab pegol which could result in a higher serum level.Metformin may decrease the excretion rate of Cetirizine which could result in a higher serum level.Cevimeline may decrease the excretion rate of Metformin which could result in a higher serum level.Metformin may decrease the excretion rate of Chloroquine which could result in a higher serum level.The therapeutic efficacy of Metformin can be decreased when used in combination with Chlorothiazide.Empagliflozin may increase the diuretic activities of Chlorothiazide.The therapeutic efficacy of Metformin can be decreased when used in combination with Chlorpromazine.The therapeutic efficacy of Metformin can be decreased when used in combination with Chlorthalidone.Empagliflozin may increase the diuretic activities of Chlorthalidone.Metformin may decrease the excretion rate of Chlorzoxazone which could result in a higher serum level.Metformin may decrease the excretion rate of Chondroitin sulfate which could result in a higher serum level.Metformin may decrease the excretion rate of Chromic chloride which could result in a higher serum level.Metformin may decrease the excretion rate of Chromium which could result in a higher serum level.Metformin may decrease the excretion rate of Chromium nicotinate which could result in a higher serum level.The therapeutic efficacy of Metformin can be decreased when used in combination with Ciclesonide.Cidofovir may decrease the excretion rate of Metformin which could result in a higher serum level.Metformin may decrease the excretion rate of Cilostazol which could result in a higher serum level.The serum concentration of Metformin can be increased when it is combined with Cimetidine.Metformin may decrease the excretion rate of Clobazam which could result in a higher serum level.The therapeutic efficacy of Metformin can be decreased when used in combination with Clobetasol propionate.Metformin may decrease the excretion rate of Clofarabine which could result in a higher serum level.The risk or severity of adverse effects can be increased when Clofarabine is combined with Empagliflozin.Metformin may decrease the excretion rate of Clonazepam which could result in a higher serum level.The risk or severity of adverse effects can be increased when Clonidine is combined with Empagliflozin.Metformin may decrease the excretion rate of Clorazepic acid which could result in a higher serum level.Metformin may decrease the excretion rate of Clove oil which could result in a higher serum level.The therapeutic efficacy of Metformin can be decreased when used in combination with Clozapine.Metformin may decrease the excretion rate of Colchicine which could result in a higher serum level.Colistimethate may decrease the excretion rate of Metformin which could result in a higher serum level.Conivaptan may increase the excretion rate of Metformin which could result in a lower serum level and potentially a reduction in efficacy.Empagliflozin may increase the diuretic activities of Conivaptan.The therapeutic efficacy of Metformin can be decreased when used in combination with Corticotropin.The therapeutic efficacy of Metformin can be decreased when used in combination with Cortisone acetate.Cyanocobalamin may decrease the excretion rate of Metformin which could result in a higher serum level.Cyclosporine may decrease the excretion rate of Metformin which could result in a higher serum level.Metformin may decrease the excretion rate of Dabigatran etexilate which could result in a higher serum level.The therapeutic efficacy of Metformin can be decreased when used in combination with Dabrafenib.Metformin may decrease the excretion rate of Dacarbazine which could result in a higher serum level.The serum concentration of Dalfampridine can be increased when it is combined with Metformin.The therapeutic efficacy of Metformin can be decreased when used in combination with Danazol.Daptomycin may decrease the excretion rate of Metformin which could result in a higher serum level.The therapeutic efficacy of Metformin can be decreased when used in combination with Darunavir.Empagliflozin may increase the hypotensive activities of Dasiglucagon.Metformin may decrease the excretion rate of Deferiprone which could result in a higher serum level.The therapeutic efficacy of Metformin can be decreased when used in combination with Deflazacort.The risk or severity of adverse effects can be increased when Desflurane is combined with Empagliflozin.Desmopressin may decrease the excretion rate of Metformin which could result in a higher serum level.The therapeutic efficacy of Metformin can be decreased when used in combination with Desogestrel.Metformin may decrease the excretion rate of Deutetrabenazine which could result in a higher serum level.The therapeutic efficacy of Metformin can be decreased when used in combination with Dexamethasone.Metformin may decrease the excretion rate of Dexmedetomidine which could result in a higher serum level.The risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Empagliflozin.Metformin may decrease the excretion rate of Dexpanthenol which could result in a higher serum level.Metformin may decrease the excretion rate of Dexrazoxane which could result in a higher serum level.Metformin may decrease the excretion rate of Dextran which could result in a higher serum level.Diatrizoate may decrease the excretion rate of Metformin which could result in a higher serum level.Metformin may decrease the excretion rate of Diazepam which could result in a higher serum level.The therapeutic efficacy of Metformin can be decreased when used in combination with Diazoxide.Diclofenac may decrease the excretion rate of Metformin which could result in a higher serum level.Empagliflozin may increase the diuretic activities of Diclofenamide.Metformin may decrease the excretion rate of Dicyclomine which could result in a higher serum level.Metformin may decrease the excretion rate of Didanosine which could result in a higher serum level.The therapeutic efficacy of Metformin can be decreased when used in combination with Dienogest.Metformin may decrease the excretion rate of Dimercaprol which could result in a higher serum level.Metformin may decrease the excretion rate of Dimethyl sulfoxide which could result in a higher serum level.The risk or severity of adverse effects can be increased when Empagliflozin is combined with Dinutuximab.The risk or severity of adverse effects can be increased when Dipyridamole is combined with Empagliflozin.Metformin may decrease the excretion rate of DL-Methylephedrine which could result in a higher serum level.Metformin may decrease the excretion rate of Dobutamine which could result in a higher serum level.Empagliflozin may increase the diuretic activities of Dorzolamide.The risk or severity of adverse effects can be increased when Doxazosin is combined with Empagliflozin.Doxycycline may decrease the excretion rate of Metformin which could result in a higher serum level.The therapeutic efficacy of Metformin can be decreased when used in combination with Drospirenone.Empagliflozin may increase the diuretic activities of Drospirenone.Metformin may decrease the excretion rate of Droxidopa which could result in a higher serum level.The risk or severity of orthostatic hypotension and syncope can be increased when Empagliflozin is combined with Duloxetine.Metformin may decrease the excretion rate of Edoxaban which could result in a higher serum level.Metformin may decrease the excretion rate of Edrophonium which could result in a higher serum level.The excretion of Emtricitabine can be decreased when combined with Metformin.The risk or severity of lactic acidosis can be increased when Enalapril is combined with Metformin.The risk or severity of lactic acidosis can be increased when Enalaprilat is combined with Metformin.Metformin may decrease the excretion rate of Enzalutamide which could result in a higher serum level.The therapeutic efficacy of Metformin can be decreased when used in combination with Epinephrine.Eplerenone may increase the excretion rate of Metformin which could result in a lower serum level and potentially a reduction in efficacy.Empagliflozin may increase the diuretic activities of Eplerenone.Metformin may decrease the excretion rate of Epoprostenol which could result in a higher serum level.The risk or severity of adverse effects can be increased when Epoprostenol is combined with Empagliflozin.The risk or severity of adverse effects can be increased when Eprosartan is combined with Empagliflozin.Ertapenem may decrease the excretion rate of Metformin which could result in a higher serum level.The risk or severity of adverse effects can be increased when Esmolol is combined with Empagliflozin.Metformin may decrease the excretion rate of Estazolam which could result in a higher serum level.The therapeutic efficacy of Metformin can be decreased when used in combination with Estradiol.The therapeutic efficacy of Metformin can be decreased when used in combination with Estrone sulfate.Metformin may decrease the excretion rate of Eszopiclone which could result in a higher serum level.The therapeutic efficacy of Metformin can be decreased when used in combination with Etacrynic acid.Empagliflozin may increase the diuretic activities of Etacrynic acid.Ethambutol may decrease the excretion rate of Metformin which could result in a higher serum level.Ethenzamide may decrease the excretion rate of Metformin which could result in a higher serum level.The therapeutic efficacy of Metformin can be decreased when used in combination with Ethinylestradiol.The therapeutic efficacy of Metformin can be decreased when used in combination with Ethynodiol diacetate.Etodolac may decrease the excretion rate of Metformin which could result in a higher serum level.Etomidate may decrease the excretion rate of Metformin which could result in a higher serum level.The therapeutic efficacy of Metformin can be decreased when used in combination with Etonogestrel.Metformin may decrease the excretion rate of Eucalyptus oil which could result in a higher serum level.Metformin may decrease the excretion rate of Evening primrose oil which could result in a higher serum level.The therapeutic efficacy of Metformin can be decreased when used in combination with Everolimus.The therapeutic efficacy of Empagliflozin can be increased when used in combination with Fedratinib.Metformin may decrease the excretion rate of Fenofibric acid which could result in a higher serum level.Metformin may decrease the excretion rate of Fenoldopam which could result in a higher serum level.The risk or severity of adverse effects can be increased when Fenoldopam is combined with Empagliflozin.Fenoprofen may decrease the excretion rate of Metformin which could result in a higher serum level.Metformin may decrease the excretion rate of Fentanyl which could result in a higher serum level.Metformin may decrease the excretion rate of Fesoterodine which could result in a higher serum level.Finerenone may increase the excretion rate of Metformin which could result in a lower serum level and potentially a reduction in efficacy.Empagliflozin may increase the diuretic activities of Finerenone.Metformin may decrease the excretion rate of Flavoxate which could result in a higher serum level.The excretion of Flecainide can be decreased when combined with Metformin.Metformin may decrease the excretion rate of Florbetaben (18F) which could result in a higher serum level.Metformin may decrease the excretion rate of Florbetapir (18F) which could result in a higher serum level.Floxuridine may decrease the excretion rate of Metformin which could result in a higher serum level.Metformin may decrease the excretion rate of Flucytosine which could result in a higher serum level.Metformin may decrease the excretion rate of Fludeoxyglucose (18F) which could result in a higher serum level.The therapeutic efficacy of Metformin can be decreased when used in combination with Fludrocortisone.Metformin may decrease the excretion rate of Flumazenil which could result in a higher serum level.The therapeutic efficacy of Metformin can be decreased when used in combination with Fluorometholone.Fluoxymesterone may increase the hypoglycemic activities of Metformin.Fluoxymesterone may increase the hypoglycemic activities of Empagliflozin.Flurbiprofen may decrease the excretion rate of Metformin which could result in a higher serum level.Metformin may decrease the excretion rate of Flutamide which could result in a higher serum level.The therapeutic efficacy of Metformin can be decreased when used in combination with Fluticasone furoate.Metformin may increase the hypolipidaemic activities of Fluvastatin.Folic acid may decrease the excretion rate of Metformin which could result in a higher serum level.Metformin may decrease the excretion rate of Fomepizole which could result in a higher serum level.Metformin may decrease the excretion rate of Fondaparinux which could result in a higher serum level.The therapeutic efficacy of Metformin can be decreased when used in combination with Fosamprenavir.Foscarnet may decrease the excretion rate of Metformin which could result in a higher serum level.Metformin may decrease the excretion rate of Fosfomycin which could result in a higher serum level.The risk or severity of lactic acidosis can be increased when Fosinopril is combined with Metformin.The risk or severity of hypotension can be increased when Fostamatinib is combined with Empagliflozin.The therapeutic efficacy of Metformin can be decreased when used in combination with Furosemide.Empagliflozin may increase the diuretic activities of Furosemide.Metformin may decrease the excretion rate of Gabapentin enacarbil which could result in a higher serum level.Metformin may decrease the excretion rate of Gadobenic acid which could result in a higher serum level.Gadodiamide may decrease the excretion rate of Metformin which could result in a higher serum level.Metformin may decrease the excretion rate of Gadofosveset trisodium which could result in a higher serum level.Metformin may decrease the excretion rate of Gadoteric acid which could result in a higher serum level.Metformin may decrease the excretion rate of Gadoteridol which could result in a higher serum level.Metformin may decrease the excretion rate of Gemcitabine which could result in a higher serum level.Metformin may decrease the excretion rate of Gemfibrozil which could result in a higher serum level.The excretion of Metformin can be decreased when combined with Gilteritinib.Givosiran may decrease the excretion rate of Metformin which could result in a higher serum level.Metformin may decrease the excretion rate of Glycerol phenylbutyrate which could result in a higher serum level.The serum concentration of Metformin can be increased when it is combined with Glycopyrronium.Metformin may decrease the excretion rate of Golodirsen which could result in a higher serum level.The therapeutic efficacy of Metformin can be decreased when used in combination with Goserelin.Metformin may decrease the excretion rate of Guanfacine which could result in a higher serum level.The risk or severity of adverse effects can be increased when Guanfacine is combined with Empagliflozin.The therapeutic efficacy of Metformin can be decreased when used in combination with Haloperidol.The therapeutic efficacy of Metformin can be decreased when used in combination with Histrelin.Metformin may decrease the excretion rate of Hydralazine which could result in a higher serum level.The risk or severity of adverse effects can be increased when Hydralazine is combined with Empagliflozin.The therapeutic efficacy of Metformin can be decreased when used in combination with Hydrochlorothiazide.Empagliflozin may increase the diuretic activities of Hydrochlorothiazide.The therapeutic efficacy of Metformin can be decreased when used in combination with Hydrocortisone.Empagliflozin may increase the diuretic activities of Hydroflumethiazide.Hydromorphone may decrease the excretion rate of Metformin which could result in a higher serum level.Hydroxocobalamin may decrease the excretion rate of Metformin which could result in a higher serum level.Metformin may decrease the excretion rate of Hydroxyethyl Starch which could result in a higher serum level.The therapeutic efficacy of Metformin can be decreased when used in combination with Hydroxyprogesterone caproate.Ibuprofen may decrease the excretion rate of Metformin which could result in a higher serum level.Ibutilide may decrease the excretion rate of Metformin which could result in a higher serum level.Metformin may decrease the excretion rate of Icatibant which could result in a higher serum level.Icosapent may decrease the excretion rate of Metformin which could result in a higher serum level.Metformin may decrease the excretion rate of Idarucizumab which could result in a higher serum level.Metformin may decrease the excretion rate of Ifosfamide which could result in a higher serum level.The therapeutic efficacy of Metformin can be decreased when used in combination with Iloperidone.The risk or severity of adverse effects can be increased when Iloprost is combined with Empagliflozin.The therapeutic efficacy of Metformin can be decreased when used in combination with Indapamide.Empagliflozin may increase the diuretic activities of Indapamide.Metformin may decrease the excretion rate of Indigotindisulfonic acid which could result in a higher serum level.The therapeutic efficacy of Metformin can be decreased when used in combination with Indinavir.Metformin may decrease the excretion rate of Inositol which could result in a higher serum level.Inotersen may decrease the excretion rate of Metformin which could result in a higher serum level.Metformin may decrease the excretion rate of Iobenguane sulfate I-123 which could result in a higher serum level.Metformin may decrease the excretion rate of Ioflupane I-123 which could result in a higher serum level.Metformin may decrease the excretion rate of Iothalamic acid which could result in a higher serum level.Metformin may decrease the excretion rate of Ipecac which could result in a higher serum level.Metformin may decrease the excretion rate of Ipilimumab which could result in a higher serum level.The risk or severity of adverse effects can be increased when Irbesartan is combined with Empagliflozin.Isocarboxazid may increase the hypoglycemic activities of Metformin.The risk or severity of adverse effects can be increased when Isoflurane is combined with Empagliflozin.The therapeutic efficacy of Metformin can be decreased when used in combination with Isoniazid.Isosorbide may increase the excretion rate of Metformin which could result in a lower serum level and potentially a reduction in efficacy.Empagliflozin may increase the diuretic activities of Isosorbide.The risk or severity of adverse effects can be increased when Isosorbide dinitrate is combined with Empagliflozin.Metformin may decrease the excretion rate of Isosorbide mononitrate which could result in a higher serum level.The risk or severity of adverse effects can be increased when Isosorbide mononitrate is combined with Empagliflozin.Metformin may decrease the excretion rate of Isosulfan blue which could result in a higher serum level.Metformin may decrease the excretion rate of Isotretinoin which could result in a higher serum level.The risk or severity of adverse effects can be increased when Isoxsuprine is combined with Empagliflozin.Metformin may decrease the excretion rate of Ixazomib which could result in a higher serum level.Metformin may decrease the excretion rate of Ketamine which could result in a higher serum level.Ketoprofen may decrease the excretion rate of Metformin which could result in a higher serum level.Ketorolac may decrease the excretion rate of Metformin which could result in a higher serum level.The risk or severity of thrombocytopenia can be increased when Metformin is combined with Ketotifen.The risk or severity of thrombocytopenia can be increased when Empagliflozin is combined with Ketotifen.Metformin may decrease the excretion rate of Lamivudine which could result in a higher serum level.The serum concentration of Metformin can be increased when it is combined with Lamotrigine.Empagliflozin may increase the hypotensive activities of Landiolol.The therapeutic efficacy of Metformin can be decreased when used in combination with Lanreotide.Metformin may decrease the excretion rate of Ledipasvir which could result in a higher serum level.Metformin may decrease the excretion rate of Lenalidomide which could result in a higher serum level.The therapeutic efficacy of Metformin can be decreased when used in combination with Leuprolide.Metformin may decrease the excretion rate of Levocarnitine which could result in a higher serum level.Metformin may decrease the excretion rate of Levocetirizine which could result in a higher serum level.The risk or severity of hypotension and orthostatic hypotension can be increased when Empagliflozin is combined with Levodopa.The therapeutic efficacy of Metformin can be decreased when used in combination with Levonorgestrel.Metformin may decrease the excretion rate of Levosalbutamol which could result in a higher serum level.The therapeutic efficacy of Empagliflozin can be decreased when used in combination with Levothyroxine.Linezolid may increase the hypoglycemic activities of Metformin.The risk or severity of lactic acidosis can be increased when Lisinopril is combined with Metformin.The therapeutic efficacy of Metformin can be decreased when used in combination with Lithium carbonate.The therapeutic efficacy of Empagliflozin can be decreased when used in combination with Lithium carbonate.Lithium citrate may decrease the excretion rate of Metformin which could result in a higher serum level.Metformin may decrease the excretion rate of Lofexidine which could result in a higher serum level.The risk or severity of adverse effects can be increased when Lofexidine is combined with Empagliflozin.The therapeutic efficacy of Metformin can be decreased when used in combination with Lopinavir.Lorazepam may decrease the excretion rate of Metformin which could result in a higher serum level.The risk or severity of adverse effects can be increased when Losartan is combined with Empagliflozin.Metformin may increase the hypolipidaemic activities of Lovastatin.Metformin may decrease the excretion rate of Lubiprostone which could result in a higher serum level.The therapeutic efficacy of Metformin can be decreased when used in combination with Lurasidone.Metformin may decrease the excretion rate of Macitentan which could result in a higher serum level.Empagliflozin may increase the hypotensive activities of Macitentan.Metformin may decrease the excretion rate of Magnesium carbonate which could result in a higher serum level.Metformin may decrease the excretion rate of Magnesium chloride which could result in a higher serum level.Metformin may decrease the excretion rate of Magnesium hydroxide which could result in a higher serum level.Magnesium salicylate may decrease the excretion rate of Metformin which could result in a higher serum level.Metformin may decrease the excretion rate of Magnesium trisilicate which could result in a higher serum level.Mannitol may decrease the excretion rate of Metformin which could result in a higher serum level.Empagliflozin may increase the diuretic activities of Mannitol.Metformin may decrease the excretion rate of Maprotiline which could result in a higher serum level.Metformin may decrease the excretion rate of Mecamylamine which could result in a higher serum level.The risk or severity of adverse effects can be increased when Mecamylamine is combined with Empagliflozin.Meclofenamic acid may decrease the excretion rate of Metformin which could result in a higher serum level.The therapeutic efficacy of Metformin can be decreased when used in combination with Medroxyprogesterone acetate.Mefenamic acid may decrease the excretion rate of Metformin which could result in a higher serum level.The therapeutic efficacy of Metformin can be decreased when used in combination with Megestrol acetate.Meloxicam may decrease the excretion rate of Metformin which could result in a higher serum level.Metformin may decrease the excretion rate of Memantine which could result in a higher serum level.Metformin may decrease the excretion rate of Meperidine which could result in a higher serum level.Metformin may decrease the excretion rate of Mepivacaine which could result in a higher serum level.Metformin may decrease the excretion rate of Meropenem which could result in a higher serum level.Metformin may decrease the excretion rate of Metamfetamine which could result in a higher serum level.Metformin may decrease the excretion rate of Metaxalone which could result in a higher serum level.Metformin may decrease the excretion rate of Methadone which could result in a higher serum level.Empagliflozin may increase the diuretic activities of Methazolamide.Metformin may decrease the excretion rate of Methimazole which could result in a higher serum level.Methotrexate may decrease the excretion rate of Metformin which could result in a higher serum level.Metformin may decrease the excretion rate of Methoxsalen which could result in a higher serum level.Metformin may decrease the excretion rate of Methyldopa which could result in a higher serum level.The risk or severity of adverse effects can be increased when Methyldopa is combined with Empagliflozin.Metformin may decrease the excretion rate of Methylnaltrexone which could result in a higher serum level.The therapeutic efficacy of Metformin can be decreased when used in combination with Methylprednisolone.Methyltestosterone may increase the hypoglycemic activities of Metformin.Methyltestosterone may increase the hypoglycemic activities of Empagliflozin.Metformin may decrease the excretion rate of Metoclopramide which could result in a higher serum level.The therapeutic efficacy of Metformin can be decreased when used in combination with Metolazone.Empagliflozin may increase the diuretic activities of Metolazone.Metformin may decrease the excretion rate of Metyrapone which could result in a higher serum level.Empagliflozin may increase the hypotensive activities of Metyrosine.Metformin may decrease the excretion rate of Midazolam which could result in a higher serum level.Metformin may decrease the excretion rate of Migalastat which could result in a higher serum level.Milrinone may decrease the excretion rate of Metformin which could result in a higher serum level.The risk or severity of adverse effects can be increased when Minoxidil is combined with Empagliflozin.Metformin may decrease the excretion rate of Mirabegron which could result in a higher serum level.The therapeutic efficacy of Metformin can be increased when used in combination with Mitapivat.The therapeutic efficacy of Empagliflozin can be increased when used in combination with Mitapivat.The risk or severity of lactic acidosis can be increased when Moexipril is combined with Metformin.The therapeutic efficacy of Metformin can be decreased when used in combination with Mometasone furoate.The risk or severity of adverse effects can be increased when Morphine is combined with Empagliflozin.Metformin may decrease the excretion rate of Mycophenolate mofetil which could result in a higher serum level.Metformin may decrease the excretion rate of Mycophenolic acid which could result in a higher serum level.Metformin may decrease the excretion rate of N-acetyltyrosine which could result in a higher serum level.The risk or severity of adverse effects can be increased when Nabilone is combined with Empagliflozin.Nabumetone may decrease the excretion rate of Metformin which could result in a higher serum level.Metformin may decrease the excretion rate of Naldemedine which could result in a higher serum level.Metformin may decrease the excretion rate of Nalmefene which could result in a higher serum level.Metformin may decrease the excretion rate of Naloxone which could result in a higher serum level.Nandrolone decanoate may increase the hypoglycemic activities of Metformin.Nandrolone decanoate may increase the hypoglycemic activities of Empagliflozin.Naproxen may decrease the excretion rate of Metformin which could result in a higher serum level.Metformin may decrease the excretion rate of Nedocromil which could result in a higher serum level.The therapeutic efficacy of Metformin can be decreased when used in combination with Nelfinavir.The therapeutic efficacy of Metformin can be decreased when used in combination with Niacin.The therapeutic efficacy of Metformin can be decreased when used in combination with Nilotinib.Metformin may decrease the excretion rate of Nilutamide which could result in a higher serum level.Metformin may decrease the excretion rate of Nitric Oxide which could result in a higher serum level.The risk or severity of adverse effects can be increased when Nitric Oxide is combined with Empagliflozin.Metformin may decrease the excretion rate of Nitrofurantoin which could result in a higher serum level.The risk or severity of adverse effects can be increased when Nitroglycerin is combined with Empagliflozin.Nitroprusside may decrease the excretion rate of Metformin which could result in a higher serum level.The risk or severity of adverse effects can be increased when Nitroprusside is combined with Empagliflozin.The risk or severity of adverse effects can be increased when Empagliflozin is combined with Nitrous acid.The therapeutic efficacy of Metformin can be decreased when used in combination with Norethisterone.The therapeutic efficacy of Metformin can be decreased when used in combination with Norgestimate.The risk or severity of adverse effects can be increased when Obinutuzumab is combined with Empagliflozin.Metformin may decrease the excretion rate of Octinoxate which could result in a higher serum level.The therapeutic efficacy of Metformin can be decreased when used in combination with Olanzapine.The risk or severity of adverse effects can be increased when Olmesartan is combined with Empagliflozin.The risk or severity of adverse effects can be increased when Empagliflozin is combined with Opicapone.Metformin may decrease the excretion rate of Opium which could result in a higher serum level.Oseltamivir may decrease the excretion rate of Metformin which could result in a higher serum level.Metformin may decrease the excretion rate of Oxacillin which could result in a higher serum level.Oxandrolone may increase the hypoglycemic activities of Metformin.Oxandrolone may increase the hypoglycemic activities of Empagliflozin.Oxaprozin may decrease the excretion rate of Metformin which could result in a higher serum level.Metformin may decrease the excretion rate of Oxazepam which could result in a higher serum level.Metformin may decrease the excretion rate of Oxybenzone which could result in a higher serum level.Oxymetholone may increase the hypoglycemic activities of Metformin.Oxymetholone may increase the hypoglycemic activities of Empagliflozin.Metformin may decrease the excretion rate of Oxyquinoline which could result in a higher serum level.The risk or severity of adverse effects can be increased when Paclitaxel is combined with Empagliflozin.The therapeutic efficacy of Metformin can be decreased when used in combination with Paliperidone.Metformin may decrease the excretion rate of Palonosetron which could result in a higher serum level.Pamidronic acid may decrease the excretion rate of Metformin which could result in a higher serum level.Pantoprazole may decrease the excretion rate of Metformin which could result in a higher serum level.The risk or severity of adverse effects can be increased when Papaverine is combined with Empagliflozin.Parecoxib may decrease the excretion rate of Metformin which could result in a higher serum level.Paromomycin may decrease the excretion rate of Metformin which could result in a higher serum level.The therapeutic efficacy of Metformin can be decreased when used in combination with Pasireotide.The therapeutic efficacy of Metformin can be decreased when used in combination with Pentamidine.Metformin may decrease the excretion rate of Pentetic acid which could result in a higher serum level.Pentobarbital may decrease the excretion rate of Metformin which could result in a higher serum level.Metformin may decrease the excretion rate of Pentoxifylline which could result in a higher serum level.The risk or severity of lactic acidosis can be increased when Perindopril is combined with Metformin.Metformin may decrease the excretion rate of Permethrin which could result in a higher serum level.Phenazopyridine may decrease the excretion rate of Metformin which could result in a higher serum level.Phenelzine may increase the hypoglycemic activities of Metformin.The risk or severity of adverse effects can be increased when Phenoxybenzamine is combined with Empagliflozin.The risk or severity of adverse effects can be increased when Phentolamine is combined with Empagliflozin.The therapeutic efficacy of Metformin can be decreased when used in combination with Phenytoin.Metformin may decrease the excretion rate of Phosphoric acid which could result in a higher serum level.Metformin may decrease the excretion rate of Phylloquinone which could result in a higher serum level.Metformin may decrease the excretion rate of Picosulfuric acid which could result in a higher serum level.Piperacillin may decrease the excretion rate of Metformin which could result in a higher serum level.Piroxicam may decrease the excretion rate of Metformin which could result in a higher serum level.Metformin may increase the hypolipidaemic activities of Pitavastatin.Metformin may decrease the excretion rate of Pitolisant which could result in a higher serum level.Metformin may decrease the excretion rate of Plerixafor which could result in a higher serum level.The therapeutic efficacy of Metformin can be decreased when used in combination with Polythiazide.Empagliflozin may increase the diuretic activities of Polythiazide.Metformin may decrease the excretion rate of Pomalidomide which could result in a higher serum level.Potassium may increase the excretion rate of Metformin which could result in a lower serum level and potentially a reduction in efficacy.Empagliflozin may increase the diuretic activities of Potassium.Metformin may decrease the excretion rate of Potassium acetate which could result in a higher serum level.Metformin may decrease the excretion rate of Potassium bicarbonate which could result in a higher serum level.Metformin may decrease the excretion rate of Potassium cation which could result in a higher serum level.Empagliflozin may increase the diuretic activities of Potassium cation.Metformin may decrease the excretion rate of Potassium chloride which could result in a higher serum level.Potassium citrate may increase the excretion rate of Metformin which could result in a lower serum level and potentially a reduction in efficacy.Empagliflozin may increase the diuretic activities of Potassium citrate.Metformin may decrease the excretion rate of Potassium nitrate which could result in a higher serum level.Metformin may decrease the excretion rate of Potassium sulfate which could result in a higher serum level.Metformin may decrease the excretion rate of Pralatrexate which could result in a higher serum level.Metformin may decrease the excretion rate of Pralidoxime which could result in a higher serum level.Metformin may decrease the excretion rate of Pramipexole which could result in a higher serum level.The risk or severity of adverse effects can be increased when Pramipexole is combined with Empagliflozin.Metformin may decrease the excretion rate of Prasugrel which could result in a higher serum level.Metformin may increase the hypolipidaemic activities of Pravastatin.The risk or severity of adverse effects can be increased when Prazosin is combined with Empagliflozin.The therapeutic efficacy of Metformin can be decreased when used in combination with Prednisolone.The therapeutic efficacy of Metformin can be decreased when used in combination with Prednisone.The therapeutic efficacy of Empagliflozin can be increased when used in combination with Probenecid.Procaine may increase the hypoglycemic activities of Metformin.Metformin may decrease the excretion rate of Procaine benzylpenicillin which could result in a higher serum level.Procarbazine may increase the hypoglycemic activities of Metformin.The therapeutic efficacy of Metformin can be decreased when used in combination with Progesterone.Metformin may decrease the excretion rate of Promethazine which could result in a higher serum level.Metformin may decrease the excretion rate of Propantheline which could result in a higher serum level.The risk or severity of adverse effects can be increased when Propofol is combined with Empagliflozin.Propyphenazone may decrease the excretion rate of Metformin which could result in a higher serum level.Metformin may decrease the excretion rate of Prucalopride which could result in a higher serum level.The therapeutic efficacy of Metformin can be decreased when used in combination with Pseudoephedrine.Metformin may decrease the excretion rate of Pyrantel which could result in a higher serum level.Metformin may decrease the excretion rate of Pyrazinamide which could result in a higher serum level.Pyridoxine may decrease the excretion rate of Metformin which could result in a higher serum level.The therapeutic efficacy of Metformin can be decreased when used in combination with Quetiapine.The risk or severity of lactic acidosis can be increased when Quinapril is combined with Metformin.Metformin may decrease the excretion rate of Rabeprazole which could result in a higher serum level.Metformin may decrease the excretion rate of Ramelteon which could result in a higher serum level.The risk or severity of lactic acidosis can be increased when Ramipril is combined with Metformin.Rasagiline may increase the hypoglycemic activities of Metformin.The excretion of Metformin can be decreased when combined with Remdesivir.The risk or severity of adverse effects can be increased when Remifentanil is combined with Empagliflozin.Reserpine may decrease the excretion rate of Metformin which could result in a higher serum level.The risk or severity of adverse effects can be increased when Reserpine is combined with Empagliflozin.Metformin may decrease the excretion rate of Resorcinol which could result in a higher serum level.Metformin may decrease the excretion rate of Ribavirin which could result in a higher serum level.The risk or severity of adverse effects can be increased when Riociguat is combined with Empagliflozin.The excretion of Metformin can be decreased when combined with Ripretinib.The therapeutic efficacy of Metformin can be decreased when used in combination with Risperidone.Empagliflozin may increase the hypotensive activities of Risperidone.The therapeutic efficacy of Metformin can be decreased when used in combination with Ritonavir.Metformin may decrease the excretion rate of Rivaroxaban which could result in a higher serum level.Metformin may decrease the excretion rate of Rizatriptan which could result in a higher serum level.Metformin may decrease the excretion rate of Roflumilast which could result in a higher serum level.The risk or severity of adverse effects can be increased when Ropinirole is combined with Empagliflozin.Ropivacaine may decrease the excretion rate of Metformin which could result in a higher serum level.The risk or severity of adverse effects can be increased when Ropivacaine is combined with Empagliflozin.The therapeutic efficacy of Empagliflozin can be increased when used in combination with Rosuvastatin.The risk or severity of adverse effects can be increased when Rotigotine is combined with Empagliflozin.Metformin may decrease the excretion rate of Ruxolitinib which could result in a higher serum level.Metformin may decrease the excretion rate of Sacubitril which could result in a higher serum level.The risk or severity of adverse effects can be increased when Empagliflozin is combined with Sacubitril.Safinamide may increase the hypoglycemic activities of Metformin.Salicylamide may decrease the excretion rate of Metformin which could result in a higher serum level.Salmon calcitonin may decrease the excretion rate of Metformin which could result in a higher serum level.Salsalate may decrease the excretion rate of Metformin which could result in a higher serum level.The therapeutic efficacy of Metformin can be decreased when used in combination with Saquinavir.Metformin may decrease the excretion rate of Secobarbital which could result in a higher serum level.Selegiline may increase the hypoglycemic activities of Metformin.Metformin may decrease the excretion rate of Selenious acid which could result in a higher serum level.Metformin may decrease the excretion rate of Selenium which could result in a higher serum level.Empagliflozin may increase the hypotensive activities of Selexipag.The excretion of Metformin can be decreased when combined with Selpercatinib.The risk or severity of adverse effects can be increased when Sevoflurane is combined with Empagliflozin.The risk or severity of hypotension can be increased when Sildenafil is combined with Empagliflozin.Metformin may increase the hypolipidaemic activities of Simvastatin.The therapeutic efficacy of Metformin can be decreased when used in combination with Sirolimus.Metformin may decrease the excretion rate of Sodium acetate which could result in a higher serum level.Metformin may decrease the excretion rate of Sodium fluoride which could result in a higher serum level.Metformin may decrease the excretion rate of Sodium sulfate which could result in a higher serum level.Metformin may decrease the excretion rate of Sofosbuvir which could result in a higher serum level.Metformin may decrease the excretion rate of Solriamfetol which could result in a higher serum level.Metformin may decrease the excretion rate of Sorafenib which could result in a higher serum level.Metformin may decrease the excretion rate of Sorbitol which could result in a higher serum level.Empagliflozin may increase the hypotensive activities of Sotatercept.Spironolactone may increase the excretion rate of Metformin which could result in a lower serum level and potentially a reduction in efficacy.Empagliflozin may increase the diuretic activities of Spironolactone.Metformin may decrease the excretion rate of Stiripentol which could result in a higher serum level.Metformin may decrease the excretion rate of Sucralfate which could result in a higher serum level.The risk or severity of adverse effects can be increased when Sufentanil is combined with Empagliflozin.Metformin may decrease the excretion rate of Sulbactam which could result in a higher serum level.The therapeutic efficacy of Metformin can be increased when used in combination with Sulfamethizole.The therapeutic efficacy of Empagliflozin can be increased when used in combination with Sulfamethizole.Sulindac may decrease the excretion rate of Metformin which could result in a higher serum level.The therapeutic efficacy of Metformin can be increased when used in combination with Sumatriptan.The therapeutic efficacy of Empagliflozin can be increased when used in combination with Sumatriptan.Metformin may decrease the excretion rate of Synthetic Conjugated Estrogens, A which could result in a higher serum level.Metformin may decrease the excretion rate of Synthetic Conjugated Estrogens, B which could result in a higher serum level.The therapeutic efficacy of Metformin can be decreased when used in combination with Tacrolimus.Metformin may decrease the excretion rate of Tadalafil which could result in a higher serum level.Empagliflozin may increase the hypotensive activities of Tadalafil.The therapeutic efficacy of Metformin can be increased when used in combination with Tamsulosin.The risk or severity of adverse effects can be increased when Tamsulosin is combined with Empagliflozin.Metformin may decrease the excretion rate of Tasimelteon which could result in a higher serum level.Metformin may decrease the excretion rate of Technetium Tc-99m exametazime which could result in a higher serum level.Metformin may decrease the excretion rate of Technetium Tc-99m pyrophosphate which could result in a higher serum level.Metformin may decrease the excretion rate of Teduglutide which could result in a higher serum level.Metformin may decrease the excretion rate of Telavancin which could result in a higher serum level.The risk or severity of adverse effects can be increased when Telmisartan is combined with Empagliflozin.Temazepam may decrease the excretion rate of Metformin which could result in a higher serum level.Metformin may decrease the excretion rate of Temozolomide which could result in a higher serum level.The therapeutic efficacy of Metformin can be decreased when used in combination with Temsirolimus.Tenofovir disoproxil may decrease the excretion rate of Metformin which could result in a higher serum level.The therapeutic efficacy of Metformin can be decreased when used in combination with Teprotumumab.The risk or severity of adverse effects can be increased when Terazosin is combined with Empagliflozin.Metformin may decrease the excretion rate of Terbutaline which could result in a higher serum level.Testosterone may increase the hypoglycemic activities of Metformin.Testosterone may increase the hypoglycemic activities of Empagliflozin.Testosterone cypionate may increase the hypoglycemic activities of Metformin.Testosterone cypionate may increase the hypoglycemic activities of Empagliflozin.Testosterone enanthate may increase the hypoglycemic activities of Metformin.Testosterone enanthate may increase the hypoglycemic activities of Empagliflozin.Testosterone propionate may increase the hypoglycemic activities of Metformin.Testosterone propionate may increase the hypoglycemic activities of Empagliflozin.Testosterone undecanoate may increase the hypoglycemic activities of Metformin.Testosterone undecanoate may increase the hypoglycemic activities of Empagliflozin.Metformin may decrease the excretion rate of Tetracycline which could result in a higher serum level.Metformin may decrease the excretion rate of Tetradecyl hydrogen sulfate (ester) which could result in a higher serum level.The risk or severity of adverse effects can be increased when Thalidomide is combined with Empagliflozin.The risk or severity of adverse effects can be increased when Thioridazine is combined with Empagliflozin.Ticlopidine may decrease the excretion rate of Metformin which could result in a higher serum level.Metformin may decrease the excretion rate of Tinidazole which could result in a higher serum level.Metformin may decrease the excretion rate of Tiopronin which could result in a higher serum level.Metformin may decrease the excretion rate of Tiotropium which could result in a higher serum level.The therapeutic efficacy of Metformin can be decreased when used in combination with Tipranavir.Metformin may decrease the excretion rate of Tirofiban which could result in a higher serum level.The risk or severity of adverse effects can be increased when Tizanidine is combined with Empagliflozin.Metformin may decrease the excretion rate of Tocopherol which could result in a higher serum level.Empagliflozin may increase the hypotensive activities of Tocopherylquinone.Tolcapone may decrease the excretion rate of Metformin which could result in a higher serum level.The risk or severity of adverse effects can be increased when Tolcapone is combined with Empagliflozin.Tolmetin may decrease the excretion rate of Metformin which could result in a higher serum level.Metformin may decrease the excretion rate of Tolterodine which could result in a higher serum level.Tolvaptan may increase the excretion rate of Metformin which could result in a lower serum level and potentially a reduction in efficacy.Empagliflozin may increase the diuretic activities of Tolvaptan.The therapeutic efficacy of Metformin can be decreased when used in combination with Torasemide.Empagliflozin may increase the diuretic activities of Torasemide.Tramadol may decrease the excretion rate of Metformin which could result in a higher serum level.Metformin may decrease the excretion rate of Trametinib which could result in a higher serum level.The risk or severity of lactic acidosis can be increased when Trandolapril is combined with Metformin.Tranylcypromine may increase the hypoglycemic activities of Metformin.Empagliflozin may increase the hypotensive activities of Treprostinil.The therapeutic efficacy of Metformin can be decreased when used in combination with Triamcinolone.Triamterene may decrease the excretion rate of Metformin which could result in a higher serum level.Empagliflozin may increase the diuretic activities of Triamterene.Metformin may decrease the excretion rate of Triazolam which could result in a higher serum level.Metformin may decrease the excretion rate of Triethylenetetramine which could result in a higher serum level.Metformin may decrease the excretion rate of Trifluridine which could result in a higher serum level.Metformin may decrease the excretion rate of Trimetrexate which could result in a higher serum level.The therapeutic efficacy of Metformin can be decreased when used in combination with Triptorelin.The serum concentration of Trospium can be decreased when it is combined with Metformin.Metformin may decrease the excretion rate of Vaborbactam which could result in a higher serum level.Valaciclovir may decrease the excretion rate of Metformin which could result in a higher serum level.Metformin may decrease the excretion rate of Valbenazine which could result in a higher serum level.The therapeutic efficacy of Metformin can be increased when used in combination with Valdecoxib.The therapeutic efficacy of Empagliflozin can be increased when used in combination with Valdecoxib.Metformin may decrease the excretion rate of Valganciclovir which could result in a higher serum level.The risk or severity of adverse effects can be increased when Valsartan is combined with Empagliflozin.The risk or severity of hypotension can be increased when Vardenafil is combined with Empagliflozin.The therapeutic efficacy of Metformin can be increased when used in combination with Vemurafenib.The therapeutic efficacy of Empagliflozin can be increased when used in combination with Vemurafenib.The risk or severity of adverse effects can be increased when Empagliflozin is combined with Vericiguat.Metformin may decrease the excretion rate of Vilanterol which could result in a higher serum level.Metformin may decrease the excretion rate of Viloxazine which could result in a higher serum level.The therapeutic efficacy of Metformin can be decreased when used in combination with Vorinostat.Metformin may decrease the excretion rate of Vortioxetine which could result in a higher serum level.Metformin may decrease the excretion rate of Zaleplon which could result in a higher serum level.Metformin may decrease the excretion rate of Zanamivir which could result in a higher serum level.The therapeutic efficacy of Metformin can be decreased when used in combination with Ziprasidone.Empagliflozin may increase the diuretic activities of Zonisamide.
A therapy excluded from this list of known interactions does not necessarily mean that no interactions exist between that therapy and and Synjardy®.
Abemaciclib
Iomeprol
Procainamide
Topotecan
Acarbose
Acebutolol
Acebutolol
Acetazolamide
Acetylsalicylic acid
Acetylsalicylic acid
Acyclovir
Alclometasone
Alclometasone
Alogliptin
Amantadine
Amcinonide
Amcinonide
Amikacin
Amiloride
Aminosalicylic acid
Aminosalicylic acid
Amiodarone
Amiodarone
Amitriptyline
Amitriptyline
Amlodipine
Amlodipine
Amobarbital
Amoxapine
Amoxapine
Apalutamide
Aripiprazole
Arsenic trioxide
Articaine
Asenapine
Atazanavir
Atenolol
Atenolol
Baclofen
Baclofen
Balsalazide
Balsalazide
Baricitinib
Beclomethasone dipropionate
Benazepril
Benazepril
Betamethasone
Betaxolol
Betaxolol
Bexagliflozin
Bexagliflozin
Bismuth subsalicylate
Bismuth subsalicylate
Bisoprolol
Bisoprolol
Brexpiprazole
Brigatinib
Bromocriptine
Bromocriptine
Budesonide
Budesonide
Bupropion
Butalbital
Canagliflozin
Capivasertib
Capmatinib
Capreomycin
Captopril
Carbamazepine
Carvedilol
Carvedilol
Cephalexin
Ceritinib
Chlorpheniramine
Chlorpromazine
Choline
Choline salicylate
Choline salicylate
Ciclesonide
Ciprofloxacin
Ciprofloxacin
Citalopram
Citalopram
Clevidipine
Clevidipine
Clobetasol propionate
Clocortolone
Clocortolone
Clomipramine
Clomipramine
Clopidogrel
Clozapine
Colistin
Conjugated estrogens
Conjugated estrogens
Corticotropin
Cortisone acetate
Crizotinib
Dabrafenib
Danazol
Dapagliflozin
Darunavir
Deflazacort
Delafloxacin
Delafloxacin
Desipramine
Desipramine
Desogestrel
Desonide
Desonide
Desoximetasone
Desoximetasone
Desvenlafaxine
Desvenlafaxine
Dexamethasone
Dexamethasone acetate
Dexamethasone acetate
Dexchlorpheniramine maleate
Diazoxide
Diclofenamide
Dienogest
Diflorasone
Diflorasone
Diflunisal
Diflunisal
Difluprednate
Difluprednate
Digoxin
Diltiazem
Diltiazem
Dinoprostone
Diphenhydramine
Disopyramide
Disopyramide
Dofetilide
Dolutegravir
Dopamine
Doxepin
Doxepin
Dronedarone
Dulaglutide
Dulaglutide
Duloxetine
Enalapril
Enalaprilat
Enasidenib
Encorafenib
Epinephrine
Erdafitinib
Ertugliflozin
Escitalopram
Escitalopram
Estetrol
Estetrol
Estradiol
Estradiol acetate
Estradiol cypionate
Estradiol valerate
Estrone sulfate
Ethanol
Ethinylestradiol
Ethosuximide
Ethosuximide
Ethynodiol diacetate
Etonogestrel
Everolimus
Exenatide
Exenatide
Famotidine
Fedratinib
Felodipine
Felodipine
Fexinidazole
Fluconazole
Fluconazole
Fludrocortisone
Flunisolide
Flunisolide
Fluocinolone acetonide
Fluocinolone acetonide
Fluocinonide
Fluocinonide
Fluorometholone
Fluoxetine
Fluoxetine
Flurandrenolide
Flurandrenolide
Flurazepam
Fluticasone furoate
Fluticasone propionate
Fluticasone propionate
Fluvoxamine
Fluvoxamine
Fosamprenavir
Fosinopril
Ganciclovir
Gatifloxacin
Gatifloxacin
Gemifloxacin
Gemifloxacin
Gentamicin
Glasdegib
Glimepiride
Glipizide
Glyburide
Goserelin
Guanidine
Halcinonide
Halcinonide
Haloperidol
Histamine
Histrelin
Hydrocortisone
Hydrocortisone acetate
Hydrocortisone acetate
Hydrocortisone butyrate
Hydrocortisone butyrate
Hydrocortisone probutate
Hydrocortisone probutate
Hydrocortisone succinate
Hydrocortisone succinate
Hydrocortisone valerate
Hydrocortisone valerate
Hydroflumethiazide
Hydroxychloroquine
Hydroxychloroquine
Hydroxyprogesterone caproate
Iloperidone
Imatinib
Imipramine
Imipramine
Indinavir
Indomethacin
Indomethacin
Insulin aspart
Insulin aspart
Insulin degludec
Insulin degludec
Insulin detemir
Insulin detemir
Insulin glargine
Insulin glargine
Insulin glulisine
Insulin glulisine
Insulin human
Insulin human
Insulin lispro
Insulin lispro
Iodixanol
Iohexol
Iopamidol
Iopromide
Ioversol
Isavuconazonium
Isocarboxazid
Isoniazid
Isradipine
Isradipine
Istradefylline
Labetalol
Labetalol
Lanreotide
Lenvatinib
Leuprolide
Levamlodipine
Levamlodipine
Levofloxacin
Levofloxacin
Levoketoconazole
Levomilnacipran
Levomilnacipran
Levonorgestrel
Levothyroxine
Linezolid
Liothyronine
Liothyronine
Lipoic acid
Liraglutide
Liraglutide
Lisinopril
Lixisenatide
Lixisenatide
Lomefloxacin
Lomefloxacin
Lonapegsomatropin
Lonapegsomatropin
Lopinavir
Lurasidone
Magnesium sulfate
Magnesium sulfate
Mecasermin
Mecasermin
Medroxyprogesterone acetate
Medrysone
Medrysone
Megestrol acetate
Mesalazine
Mesalazine
Methazolamide
Methohexital
Methsuximide
Methsuximide
Methyl salicylate
Methyl salicylate
Methylene blue
Methylene blue
Methylprednisolone
Methylprednisolone hemisuccinate
Methylprednisolone hemisuccinate
Metoprolol
Metoprolol
Mifepristone
Mifepristone
Miglitol
Milnacipran
Milnacipran
Moexipril
Mometasone furoate
Moxifloxacin
Moxifloxacin
Nadolol
Nadolol
Nateglinide
Nebivolol
Nebivolol
Nefazodone
Nefazodone
Nelfinavir
Neomycin
Niacin
Nicardipine
Nicardipine
Nicotine
Nifedipine
Nifedipine
Nilotinib
Nimodipine
Nimodipine
Nisoldipine
Nisoldipine
Norepinephrine
Norethisterone
Norgestimate
Nortriptyline
Nortriptyline
Octreotide
Octreotide
Ofloxacin
Ofloxacin
Olanzapine
Olsalazine
Olsalazine
Paliperidone
Paroxetine
Paroxetine
Pasireotide
Patiromer
Pegvisomant
Pegvisomant
Pemetrexed
Pentamidine
Pentobarbital
Pentostatin
Perindopril
Pexidartinib
Phenelzine
Phenobarbital
Phenoxybenzamine
Phentermine
Phentermine
Phenytoin
Pinaverium
Pinaverium
Pindolol
Pindolol
Pioglitazone
Plazomicin
Pralsetinib
Pramlintide
Pramlintide
Prednicarbate
Prednicarbate
Prednisolone
Prednisolone acetate
Prednisolone acetate
Prednisolone phosphate
Prednisolone phosphate
Prednisone
Pregabalin
Pregabalin
Primidone
Probenecid
Procaine
Procarbazine
Progesterone
Propafenone
Propafenone
Propranolol
Propranolol
Protriptyline
Protriptyline
Pseudoephedrine
Pyrimethamine
Quetiapine
Quinapril
Quinidine
Quinine
Quinine
Ramipril
Ranitidine
Ranolazine
Rasagiline
Relebactam
Repaglinide
Repotrectinib
Risdiplam
Ritonavir
Rosiglitazone
Safinamide
Salicylic acid
Salicylic acid
Salmeterol
Saquinavir
Saxagliptin
Secobarbital
Selegiline
Semaglutide
Semaglutide
Sertraline
Sertraline
Sirolimus
Sitagliptin
Sodium ferric gluconate complex
Somapacitan
Somapacitan
Somatotropin
Somatotropin
Somatrogon
Somatrogon
Sotagliflozin
Sotagliflozin
Sotalol
Sotalol
Streptomycin
Sulfadiazine
Sulfadiazine
Sulfamethoxazole
Sulfamethoxazole
Sulfasalazine
Sulfasalazine
Sunitinib
Sunitinib
Tacrolimus
Tafenoquine
Tazemetostat
Temsirolimus
Tenofovir alafenamide
Teprotumumab
Thiamine
Thyroid, porcine
Thyroid, porcine
Thyrotropin alfa
Thyrotropin alfa
Timolol
Timolol
Tipranavir
Tirzepatide
Tirzepatide
Tixocortol
Tixocortol
Tobramycin
Tolazamide
Tolazamide
Topiramate
Trandolapril
Tranylcypromine
Triamcinolone
Trilaciclib
Trimethoprim
Trimipramine
Trimipramine
Triptorelin
Trolamine salicylate
Trolamine salicylate
Trovafloxacin
Trovafloxacin
Tucatinib
Ubidecarenone
Ubidecarenone
Ulobetasol
Ulobetasol
Vamorolone
Vamorolone
Vancomycin
Vandetanib
Varenicline
Venlafaxine
Venlafaxine
Verapamil
Verapamil
Vimseltinib
Vorinostat
Warfarin
Xylometazoline
Xylometazoline
Ziconotide
Ziconotide
Ziprasidone
Zonisamide
Abacavir
Abaloparatide
Acarbose
Aceclofenac
Acetazolamide
Acetyl sulfisoxazole
Acetyl sulfisoxazole
Aclidinium
Acrivastine
Adefovir dipivoxil
Albuterol
Albuterol
Albutrepenonacog alfa
Aldesleukin
Aldesleukin
Aliskiren
Allopurinol
Almasilate
Almotriptan
Alprazolam
Ambrisentan
Amifostine
Amiloride
Ammonium chloride
Amoxicillin
Amphetamine
Amphotericin B
Amphotericin B
Ampicillin
Amyl Nitrite
Antipyrine
Antithrombin III human
Apomorphine
Apremilast
Aprocitentan
Arformoterol
Arimoclomol
Aripiprazole
Aripiprazole lauroxil
Arsenic trioxide
Articaine
Asenapine
Atazanavir
Atomoxetine
Atorvastatin
Auranofin
Avanafil
Azacitidine
Azathioprine
Azelaic acid
Azilsartan medoxomil
Aztreonam
Bacitracin
Beclomethasone dipropionate
Bendroflumethiazide
Bendroflumethiazide
Benzatropine
Benznidazole
Bepotastine
Betamethasone
Bicisate
Bictegravir
Bismuth subgallate
Bleomycin
Bosentan
Bosentan
Bretylium
Brexpiprazole
Brinzolamide
Brivaracetam
Bromotheophylline
Bromotheophylline
Bumetanide
Bumetanide
Bupivacaine
Buspirone
Candesartan cilexetil
Capecitabine
Captopril
Carbidopa
Carboplatin
Carmustine
Cefaclor
Cefadroxil
Cefazolin
Cefdinir
Cefditoren
Cefepime
Cefotaxime
Cefotetan
Cefoxitin
Cefpodoxime
Cefprozil
Ceftaroline fosamil
Ceftazidime
Ceftibuten
Ceftizoxime
Ceftolozane
Ceftriaxone
Cefuroxime
Celecoxib
Celecoxib
Ceritinib
Certolizumab pegol
Cetirizine
Cevimeline
Chloroquine
Chlorothiazide
Chlorothiazide
Chlorpromazine
Chlorthalidone
Chlorthalidone
Chlorzoxazone
Chondroitin sulfate
Chromic chloride
Chromium
Chromium nicotinate
Ciclesonide
Cidofovir
Cilostazol
Cimetidine
Clobazam
Clobetasol propionate
Clofarabine
Clofarabine
Clonazepam
Clonidine
Clorazepic acid
Clove oil
Clozapine
Colchicine
Colistimethate
Conivaptan
Conivaptan
Corticotropin
Cortisone acetate
Cyanocobalamin
Cyclosporine
Dabigatran etexilate
Dabrafenib
Dacarbazine
Dalfampridine
Danazol
Daptomycin
Darunavir
Dasiglucagon
Deferiprone
Deflazacort
Desflurane
Desmopressin
Desogestrel
Deutetrabenazine
Dexamethasone
Dexmedetomidine
Dexmedetomidine
Dexpanthenol
Dexrazoxane
Dextran
Diatrizoate
Diazepam
Diazoxide
Diclofenac
Diclofenamide
Dicyclomine
Didanosine
Dienogest
Dimercaprol
Dimethyl sulfoxide
Dinutuximab
Dipyridamole
DL-Methylephedrine
Dobutamine
Dorzolamide
Doxazosin
Doxycycline
Drospirenone
Drospirenone
Droxidopa
Duloxetine
Edoxaban
Edrophonium
Emtricitabine
Enalapril
Enalaprilat
Enzalutamide
Epinephrine
Eplerenone
Eplerenone
Epoprostenol
Epoprostenol
Eprosartan
Ertapenem
Esmolol
Estazolam
Estradiol
Estrone sulfate
Eszopiclone
Etacrynic acid
Etacrynic acid
Ethambutol
Ethenzamide
Ethinylestradiol
Ethynodiol diacetate
Etodolac
Etomidate
Etonogestrel
Eucalyptus oil
Evening primrose oil
Everolimus
Fedratinib
Fenofibric acid
Fenoldopam
Fenoldopam
Fenoprofen
Fentanyl
Fesoterodine
Finerenone
Finerenone
Flavoxate
Flecainide
Florbetaben F-18
Florbetapir F-18
Floxuridine
Flucytosine
Fludeoxyglucose (18F)
Fludrocortisone
Flumazenil
Fluorometholone
Fluoxymesterone
Fluoxymesterone
Flurbiprofen
Flutamide
Fluticasone furoate
Fluvastatin
Folic acid
Fomepizole
Fondaparinux
Fosamprenavir
Foscarnet
Fosfomycin
Fosinopril
Fostamatinib
Furosemide
Furosemide
Gabapentin enacarbil
Gadobenic acid
Gadodiamide
Gadofosveset trisodium
Gadoteric acid
Gadoteridol
Gemcitabine
Gemfibrozil
Gilteritinib
Givosiran
Glycerol phenylbutyrate
Glycopyrronium
Golodirsen
Goserelin
Guanfacine
Guanfacine
Haloperidol
Histrelin
Hydralazine
Hydralazine
Hydrochlorothiazide
Hydrochlorothiazide
Hydrocortisone
Hydroflumethiazide
Hydromorphone
Hydroxocobalamin
Hydroxyethyl Starch
Hydroxyprogesterone caproate
Ibuprofen
Ibutilide
Icatibant
Icosapent
Idarucizumab
Ifosfamide
Iloperidone
Iloprost
Indapamide
Indapamide
Indigotindisulfonic acid
Indinavir
Inositol
Inotersen
Iobenguane sulfate I-123
Ioflupane I-123
Iothalamic acid
Ipecac
Ipilimumab
Irbesartan
Isocarboxazid
Isoflurane
Isoniazid
Isosorbide
Isosorbide
Isosorbide dinitrate
Isosorbide mononitrate
Isosorbide mononitrate
Isosulfan blue
Isotretinoin
Isoxsuprine
Ixazomib
Ketamine
Ketoprofen
Ketorolac
Ketotifen
Ketotifen
Lamivudine
Lamotrigine
Landiolol
Lanreotide
Ledipasvir
Lenalidomide
Leuprolide
Levocarnitine
Levocetirizine
Levodopa
Levonorgestrel
Levosalbutamol
Levothyroxine
Linezolid
Lisinopril
Lithium carbonate
Lithium carbonate
Lithium citrate
Lofexidine
Lofexidine
Lopinavir
Lorazepam
Losartan
Lovastatin
Lubiprostone
Lurasidone
Macitentan
Macitentan
Magnesium carbonate
Magnesium chloride
Magnesium hydroxide
Magnesium salicylate
Magnesium trisilicate
Mannitol
Mannitol
Maprotiline
Mecamylamine
Mecamylamine
Meclofenamic acid
Medroxyprogesterone acetate
Mefenamic acid
Megestrol acetate
Meloxicam
Memantine
Meperidine
Mepivacaine
Meropenem
Metamfetamine
Metaxalone
Methadone
Methazolamide
Methimazole
Methotrexate
Methoxsalen
Methyldopa
Methyldopa
Methylnaltrexone
Methylprednisolone
Methyltestosterone
Methyltestosterone
Metoclopramide
Metolazone
Metolazone
Metyrapone
Metyrosine
Midazolam
Migalastat
Milrinone
Minoxidil
Mirabegron
Mitapivat
Mitapivat
Moexipril
Mometasone furoate
Morphine
Mycophenolate mofetil
Mycophenolic acid
N-acetyltyrosine
Nabilone
Nabumetone
Naldemedine
Nalmefene
Naloxone
Nandrolone decanoate
Nandrolone decanoate
Naproxen
Nedocromil
Nelfinavir
Niacin
Nilotinib
Nilutamide
Nitric Oxide
Nitric Oxide
Nitrofurantoin
Nitroglycerin
Nitroprusside
Nitroprusside
Nitrous acid
Norethisterone
Norgestimate
Obinutuzumab
Octinoxate
Olanzapine
Olmesartan
Opicapone
Opium
Oseltamivir
Oxacillin
Oxandrolone
Oxandrolone
Oxaprozin
Oxazepam
Oxybenzone
Oxymetholone
Oxymetholone
Oxyquinoline
Paclitaxel
Paliperidone
Palonosetron
Pamidronic acid
Pantoprazole
Papaverine
Parecoxib
Paromomycin
Pasireotide
Pentamidine
Pentetic acid
Pentobarbital
Pentoxifylline
Perindopril
Permethrin
Phenazopyridine
Phenelzine
Phenoxybenzamine
Phentolamine
Phenytoin
Phosphoric acid
Phylloquinone
Picosulfuric acid
Piperacillin
Piroxicam
Pitavastatin
Pitolisant
Plerixafor
Polythiazide
Polythiazide
Pomalidomide
Potassium
Potassium
Potassium acetate
Potassium bicarbonate
Potassium cation
Potassium cation
Potassium chloride
Potassium citrate
Potassium citrate
Potassium nitrate
Potassium sulfate
Pralatrexate
Pralidoxime
Pramipexole
Pramipexole
Prasugrel
Pravastatin
Prazosin
Prednisolone
Prednisone
Probenecid
Procaine
Procaine benzylpenicillin
Procarbazine
Progesterone
Promethazine
Propantheline
Propofol
Propyphenazone
Prucalopride
Pseudoephedrine
Pyrantel
Pyrazinamide
Pyridoxine
Quetiapine
Quinapril
Rabeprazole
Ramelteon
Ramipril
Rasagiline
Remdesivir
Remifentanil
Reserpine
Reserpine
Resorcinol
Ribavirin
Riociguat
Ripretinib
Risperidone
Risperidone
Ritonavir
Rivaroxaban
Rizatriptan
Roflumilast
Ropinirole
Ropivacaine
Ropivacaine
Rosuvastatin
Rotigotine
Ruxolitinib
Sacubitril
Sacubitril
Safinamide
Salicylamide
Salmon calcitonin
Salsalate
Saquinavir
Secobarbital
Selegiline
Selenious acid
Selenium
Selexipag
Selpercatinib
Sevoflurane
Sildenafil
Simvastatin
Sirolimus
Sodium acetate
Sodium fluoride
Sodium sulfate
Sofosbuvir
Solriamfetol
Sorafenib
Sorbitol
Sotatercept
Spironolactone
Spironolactone
Stiripentol
Sucralfate
Sufentanil
Sulbactam
Sulfamethizole
Sulfamethizole
Sulindac
Sumatriptan
Sumatriptan
Synthetic Conjugated Estrogens, A
Synthetic Conjugated Estrogens, B
Tacrolimus
Tadalafil
Tadalafil
Tamsulosin
Tamsulosin
Tasimelteon
Technetium Tc-99m exametazime
Technetium Tc-99m pyrophosphate
Teduglutide
Telavancin
Telmisartan
Temazepam
Temozolomide
Temsirolimus
Tenofovir disoproxil
Teprotumumab
Terazosin
Terbutaline
Testosterone
Testosterone
Testosterone cypionate
Testosterone cypionate
Testosterone enanthate
Testosterone enanthate
Testosterone propionate
Testosterone propionate
Testosterone undecanoate
Testosterone undecanoate
Tetracycline
Tetradecyl hydrogen sulfate (ester)
Thalidomide
Thioridazine
Ticlopidine
Tinidazole
Tiopronin
Tiotropium
Tipranavir
Tirofiban
Tizanidine
Tocopherol
Tocopherylquinone
Tolcapone
Tolcapone
Tolmetin
Tolterodine
Tolvaptan
Tolvaptan
Torasemide
Torasemide
Tramadol
Trametinib
Trandolapril
Tranylcypromine
Treprostinil
Triamcinolone
Triamterene
Triamterene
Triazolam
Triethylenetetramine
Trifluridine
Trimetrexate
Triptorelin
Trospium
Vaborbactam
Valaciclovir
Valbenazine
Valdecoxib
Valdecoxib
Valganciclovir
Valsartan
Vardenafil
Vemurafenib
Vemurafenib
Vericiguat
Vilanterol
Viloxazine
Vorinostat
Vortioxetine
Zaleplon
Zanamivir
Ziprasidone
Zonisamide